Supplemental Information for *"Meta-analysis of cannabinoid ligand binding affinity and cannabinoid receptor distribution: interspecies differences,"* by McPartland, Glass, Pertwee

Table S-1
Chronologically-listed studies regarding the affinity of cannabinoid ligands for human (*Hs*) and rat (*Rn*) cannabinoid receptors, measured by displacement of radioligands as described in footnotes

ligand[1]	reference, notes[2]	*Hs*CB_1 affinity[3]	*Rn*CB_1 affinity[3]	*Hs*CB_2 affinity[3]	*Rn*CB_2 affinity[3]	Direct comparisons[4]
THC	Harris et al., 1978; [^{3}H]Δ^8-THC, native hepatoma cells		0.001[5] Ø SE n=?			
THC	Nye et al., 1985 [^{3}H]TMA, nativeB		27.3[5] ± 5.0 SE n=6			
THC	Devane et al., 1988; [^{3}H]CP, nativeC, Centri		1.6 ± 0.06 SE n=3			
THC	Herkenham et al., 1990; [^{3}H]CP, nativeA, Sect		420 ± 51 SD n=?			
THC	Bridgen et al., 1990 [^{3}H]CP, nativeC,		143.4 Ø SE n=?			
THC	Devane et al., 1992a; [^{3}H]HU, nativeB, Centri		46 ± 3 SE n=3			
THC	Felder et al., 1992 [^{3}H]CP CB1trans5	53.3 ±8.3 SE n=3				
THC	Thomas et al., 1992; [^{3}H]THC-DMH, nativeF, Sect		2200 ± 100 SE n=3			
THC	Bouaboula et al., 1993 [^{3}H]CP, nativeH			0.07 ± 0.08 S? n=2		
THC	Compton et al., 1993 [^{3}H]CP, nativeC		40.7 ± 1.7 SE n~4.5			
THC	Houston + Howlett, 1993 [^{3}H]CP, nativeC		24.1 ± 3.2 SE n=3			

THC	Munro et al., 1993 [^{3}H]CP, trans3			320 ± 80 S? n=4		
THC	Rinaldi-Carmona et al., 1994 [^{3}H]CP, CB1nativeC, CB2nativeJ		35.3 ±5 SE n=4		3.9 ± 0.95 SE n=3	*Rn 1:2:*9.1 N:N
THC	Lynn + Herkenham, 1994; [^{3}H]CP, nativeJ, Sect		(cited Herkenham et al., 1990)		700 ± 8 SD n=2	
THC	Bayewitch et al., 1995; [^{3}H]HU, trans2, Centri			39 ± 5 SE n=?		
THC	Bouabola et al., 1995 [^{3}H]CP, trans2	3.89 ± 0.6 SE n=?				
THC	Bouaboula et al., 1995; [^{3}H]CP, native U373 astrocytoma cell	16.8 ± 12 SE n=2				
THC	Felder et al., 1995 [^{3}H]CP CB1trans5, CB2trans1	(cited Felder et al., 1992)		75.3 ± 8.4 SE n=3		*Hs 1:2:* 0.7 T:T
THC	Hillard et al., 1995 [^{3}H]CP, nativeC		52 ± 5 SE n=5			
THC	Slipetz et al., 1995 [^{3}H]WIN, trans3			24.7 ± 2.3 SE n~5		
THC	Welch et al., 1995; [^{3}H]CP, native spinal cord		300 ± 800 SE n=3			
THC	Bayewitch et al., 1996; [^{3}H]HU, trans3, Centri		39.5 ± 3 SE n=?	40.0 ± 6 SE n=?		
THC	Hirst et al., 1996 [^{3}H]SR, nativeD		51 ± 22 SE n=6			
THC	Petitet et al., 1996 [^{3}H]SR, [^{3}H]WIN, nativeD		[^{3}H]SR 35 ± 0.5 SE n~5 [^{3}H]WIN 47 ± 9 SE n~5			
THC	Rinaldi-Carmona et al., 1996a		40.5 ±4.0 SE n=3			

	[^{3}H]SR, nativeB,					
THC	Rinaldi-Carmona et al., 1996b [^{3}H]CP, trans2	7.1 ± 0.4 SE n=3				
THC	Shire et al., 1996 [^{3}H]CP, trans3,			16.0 ± 5.0 SE n=4		
THC	Showalter et al., 1996 [^{3}H]CP, trans2	21 Ø SE n~4		36.4 ± 10 SE n~4		*Hs 1:2:* 0.6 T:T
THC	Gifford et al., 1997 [^{3}H]SR, nativeE		1700 ±? n=?			
THC	Rhee et al., 1997 [^{3}H]HU, CB1nativeB and trans3, CB2trans3, Centri		nativeB: 66.5 ± 5.8 SE n=3 trans3: 80.3 ± 22.2 SE n=3	32.2 ± 6.7 SE n=3		
THC	Sheskin et al., 1997 [^{3}H]HU, nativeB, Centri		(cited Devane et al., 1992a)			
THC	Bonhaus et al., 1998 [^{3}H]CP, trans2	32 ± 15 SE n=6				
THC	Tao & Abood, 1998 [^{3}H]CP trans4	33.6 ± 9.5 SE n=3		44.9 ± 12.6 SE n=3		*Hs 1:2:*0.8 T:T
THC	Thomas et al., 1998 [^{3}H]CP, [^{3}H]SR, nativeB		[^{3}H]CP: 37 ± 2.98 SE n=5 [^{3}H]SR:119 ± 18.9 SE n=3			
THC	Griffin et al., 1999 [^{3}H]SR, nativeD		68.7 ± 4.68 SE n~4.5			
THC	Kearn et al., 1999 [^{3}H]CP, [^{3}H]SR, nativeD		[^{3}H]CP: 28.4 ± 9 SE [^{3}H]SR: 49.8 ± 17 SE all n=4			
THC	Tao et al., 1999 [^{3}H]CP or [^{3}H]WIN, trans4			44.9 ± 21.8 SE n=3		
THC	Breivogel & Childers, 2000 [^{3}H]SR, nativeD, nativeE,		nativeD: 110 ± 52 SE nativeE: 170 ± 82 SE hypothalamus:			

	native hypothalamus		37 ± 15 SE all n=4			
THC	Griffin et al., 2000 [wrong rat sequence] [^{3}H]CP, trans4,			(cited Tao et al., 1999)	28.3 ± 0.06 SE n=2	
THC	Iwamura et al., 2001; [^{3}H]CP, *Hs*CB1+CB2 trans2, *Rn*CB1+CB2 nativeD+nativeK	5.05 ± 0.65 SE n=3	13.5 ± 3.81 SE n=3	3.13 ± 0.34 SE n=3	6.80 ± 2.28 SE n=3	*H1:R1:* 0.4 T:N *H2:R2:* 0.5 T:N *Hs 1:2:*1.6 T:T *Rn 1:2:*2.0 N:N
THC	Mauler et al., 2002; [^{3}H]BAY, *Hs*CB1trans0, *Hs*CB1nativeC, *Rn*CB1nativeC, *Hs*CB2trans0	nativeC:13.7 ± 1.6 SD trans0: 15.3 ± 1.6 SD all n=3	77.3 ± 10.2 SD n=3	25.06 ± 7.14 SD n=3		*H1:R1:*0. 2 N:N *H1:R1:*0.2 T:N *Hs 1:2:*0.6 N:T *Hs 1:2:*0.6 T:T
THC	McAllister et al., 2002 [^{3}H]CP, trans4	37 ± 20.2 SE n=3		33 ± 21.4 SE n=3		*Hs 1:2:*0.9 T:T *H1:R1:*0. 2 N:N
THC	Marchese et al., 2003 ; [^{3}H]CP, nativeD		21.2 ± 0.81 SE n=4			
THC	De Vry et al., 2004; [^{3}H]BAY, CB1nativeC, CB2trans0	(cited Mauler et al., 2002)	69.7 ± 11.6 SD n=3	22.9 ± 7.8 SD n=3		*Hs 1:2:*0.7 T:T
THC	Govaerts et al., 2004b *Hs*CB1 trans2 - [^{3}H]CP; *Hs*CB2 trans2 - [^{3}H]WIN; *Rn*CB1 nativeD - [^{3}H]SR	32.4 ± 0.6 SE n~5	209 ± 175 SE n~5	309 ± 109 SE n~5		*H1:R1:*0.15 T:N *Hs 1:2:*0.1 T:T
THC	Steffens et al., 2004; [^{3}H]CP, nativeC, nativeAmygdala	nativeD:19.5 ± 1.7 SE amygdala:17.8 ± 0.3 SE all n=3				
THC	Fride et al., 2005, [^{3}H]HU, Centri, CB1nativeB, CB2trans3		46 ± 3 S? n=3	32 Ø SE n=3		
THC	Picone et al., 2005 [^{3}H]CP, trans2	89.9 ± 1.0 SE n=3				

THC	Ryberg et al., 2005 [^{3}H]CP, trans4	3.17 ± 1.2 SE n=5				
THC	Martin et al., 2006 [^{3}H]CP, *Rn*CB1 nativeA, *Hs*CB2 trans2		41± 3 SE n=3	94 ± 4 SE n=3		
CBD	Nye et al., 1985 [^{3}H]TMA, nativeB		73.1 ± 2.2 SE n=6			
CBD	Devane et al., 1988; [^{3}H]CP, nativeC, Centri		>500 Ø SE n=3			
CBD	Herkenham et al., 1990; [^{3}H]CP, nativeA, Sect		53,000 ± 6700 SD n=?			
CBD	Compton et al., 1993 [^{3}H]CP, nativeC		4350 ± 390 SE n~4.5			
CBD	Houston + Howlett, 1993 [^{3}H]CP, nativeC		>3000 Ø SE n=3			
CBD	Munro et al., 1993 [^{3}H]CP, trans3			38,000 ± 18000 S? n=4		
CBD	Lynn & Herkenham, 1994; [^{3}H]CP, nativeJ, Sect		(cited Herkenham et al., 1990)		41,800 ± 3200 SD n=2	
CBD	Facci et al., 1995 [^{3}H]WIN, nativeN				>1000 Ø SE n=3	
CBD	Hillard et al., 1995 [^{3}H]CP, nativeC		>2000 Ø SD n=5			
CBD	Petitet et al., 1996 [^{3}H]SR, [^{3}H]WIN, nativeD		[^{3}H]SR:1130 ± 380 SE n~5 [^{3}H]WIN 1130 Ø SE n~5			
CBD	Showalter et al., 1996 [^{3}H]CP, trans2		(cited Compton et al., 1993)	2860 ± 1230 SE n~4		
CBD	Thomas et al., 1998 [^{3}H]CP, [^{3}H]SR, nativeB		[^{3}H]CP:2283 ± 453 SE n=4 [^{3}H]SR:1258 ± 147 SE			

			n=3			
CBD	Bisogno et al., 2001 [^{3}H]HU, CB1nativeB, CB2trans3, Sect		>10,000 ØSE n=2	>10,000 ØSE n=2		
CBN	Nye et al., 1985 [^{3}H]TMA, nativeB		34.4 ± 10.9 SE n=6			
CBN	Devane et al., 1988; [^{3}H]CP, nativeC, Centri		13 ± 5.8 SE n=3			
CBN	Herkenham et al., 1990; [^{3}H]CP, nativeA, Sect		3200 ± 450 SD n=?			
CBN	Houston & Howlett, 1993 [^{3}H]CP, nativeC		159 ± 23 SE n=3			
CBN	Munro et al., 1993 [^{3}H]CP, trans3			250 ± 80 S? n=4		
CBN	Vogel et al., 1994 [^{3}H]HU, trans3, ØPMSF, Centri		1336 ± 145 S? n=?	211 ± 26 S? n=?		
CBN	Felder et al., 1995 [^{3}H]CP CB1trans5, CB2trans1	1130 ± 190 SE n=3		301 ± 110 SE n=3		*Hs 1:2:*3.8 T:T
CBN	Hillard et al., 1995 [^{3}H]CP, nativeC		496 ± 80 SE n=5			
CBN	Welch et al., 1995; [^{3}H]CP, native spinal cord		290 ± 50 SE n=3			
CBN	Showalter et al., 1996 [^{3}H]CP, trans2	326 Ø SE n~4		96.3 ± 14.4 SE n~4		*Hs 1:2:*3.4 T:T
CBN	Rhee et al., 1997 [^{3}H]HU, CB1nativeB and trans3, CB2trans3, Centri		nativeB: 392.2 ± 53.5 SE trans3: 211.1 ± 35.0 SE all n=3	126.4 ± 26.0 SE n=3		
CBN	Thomas et al., 1998 [^{3}H]CP, [^{3}H]SR, nativeB		[^{3}H]CP:247 ± 18.1 SE n=4 [^{3}H]SR: 743 ± 68.1 SE			

			n=3			
CBN	MacLennan et al., 1998; [^{3}H]CP, trans2	120 ± 40 SE n=5		100 ± 24 SE n=5		*Hs 1:2:*1.2 T:T
CBN	Tao et al., 1999 [^{3}H]CP or [^{3}H]WIN, trans4			92.7 ± 18.4 SE n=3		
AEA	Devane et al., 1992b; [^{3}H]HU, nativeB, ØPMSF, Centri		52 ± 1.8 SE n=3			
AEA	Felder et al., 1993 [^{3}H]CP CB1trans5, ØPMSF	543 ± 83 SE n=3				
AEA	Munro et al., 1993 [^{3}H]CP, trans3, ØPMSF			1600 ± 400 S? n=4		
AEA	Vogel et al., 1993; [^{3}H]HU, trans2, ØPMSF, Centri		37 ± 3 SE n=3			
AEA	Abadji et al., 1994 [^{3}H]CP, nativeC, +PMSF, ØPMSF		+PMSF: 78 ± 2 SE ØPMSF: 1180 ØSE all n=3			
AEA	Childers et al., 1994 IC50 [^{3}H]WIN, nativeD, +PMSF, ØPMSF		+PMSF:60.4 ±7.4 S? ØPMSF: 671 Ø S? all n=3			
AEA	Koutek et al., 1994 [^{3}H]CP, nativeB, +PMSF		16 ØSE, n=3			
AEA	Smith et al., 1994 [^{3}H]CP, nativeB, +PMSF, ØPMSF		+PMSF:101 ± 15 SE ØPMSF:5400 ± 1.55 SE all n=3			
AEA	Vogel et al., 1994 [^{3}H]HU, trans3, ØPMSF, Centri		155 ± 15 S? n=?			
AEA	Adams et al., 1995 [^{3}H]CP, nativeB +PMSF,		+PMSF: 89 ± 10 SE n~4.5 ØPMSF: 5400 ± 1600			

	ØPMSF		SE n=3			
AEA	Bayewitch et al., 1995; [^{3}H]HU, trans2, ØPMSF, Centri			85 ± 13 SE n=?		
AEA	Facci et al., 1995 [^{3}H]WIN, nativeN, ØPMSF				29.9 ± 26.3 SE n=5	
AEA	Felder et al., 1995; [^{3}H]CP CB1trans5, CB2trans1, +PMSF	(cited Felder et al., 1992)		1940 ± 240 SE n=3		*Hs 1:2:*0.3 T:T
AEA	Hampson et al., 1995 [^{3}H]CP, nativeA, +PMSF		71 ± 4.1 SE n=3			
AEA	Hillard et al., 1995 [^{3}H]CP, nativeC, +PMSF, ØPMSF		+PMSF:143 ± 37 SE ØPMSF:1290 ± 140 SE all n=5			
AEA	Mechoulam et al., 1995; [^{3}H]HU, trans3, ØPMSF, Centri		252 ± 47 SE n=3	581 ± 111 SE n=3		
AEA	Priller et al., 1995; [^{3}H]CP CB1trans5, CB2trans1, ØPMSF	781 ± 38 SD n=2		1620 ± 430 SD n=2		
AEA	Slipetz et al., 1995 [^{3}H]WIN, trans3, ØPMSF			90.3 ± 5.1 SE n~5		
AEA	Sugiura et al., 1995 [^{3}H]CP, nativeC, +DPFP		89 Ø SD n=3			
AEA	Welch et al., 1995; [^{3}H]CP, native spinal cord, +PMSF, ØPMSF		+PMSF: 214 ± 45 SE n=3 ØPMSF: 752 Ø SE n=?			
AEA	Boring et al., 1996 [^{3}H]CP, nativeA +AEBSF		80 Ø SE n=3			
AEA	Hirst et al., 1996 [^{3}H]SR, nativeD, +PMSF,		+PMSF: 550 ± 167 SE n=3 ØPMSF:1202 ± 111			

	ØPMSF		SE n=4			
AEA	Khanolkar et al., 1996 [^{3}H]CP, nativeC +PMSF, ØPMSF		+PMSF: 78.2 ± 1.6 SE ØPMSF: 1920 ± 4.5 SE all n=3			
AEA	Petitet et al., 1996 [^{3}H]SR, nativeD +PMSF, ØPMSF		+PMSF: 44 Ø SE n~5 ØPMSF: 384 ± 100 SE n~5			
AEA	Rinaldi-Carmona et al., 1996a [^{3}H]SR, nativeB, ØPMSF		152.9 ± 11.5 SE n=3			
AEA	Rinaldi-Carmona et al., 1996b [^{3}H]CP, trans2, ØPMSF	359.6 ±29.5 SE n=3				
AEA	Shire et al., 1996 [^{3}H]CP, trans3 ØPMSF			239 ± 88 SE n=4		
AEA	Showalter et al., 1996 [^{3}H]CP, trans2, ØPMSF		(cited Adams et al., 1995b)	371 ± 102 SE n~4		
AEA	Song & Bonner, 1996 [^{3}H]WIN, trans4, ØPMSF	115.6 ± 1.9 SE n=3				
AEA	Wise et al., 1996 [^{3}H]CP, nativeA +PMSF		97 ± 7 SE n=2			
AEA	Deutsch et al., 1997; [^{3}H]AEA, native renal endothelium +PMSF		Kd 27.4 ± 5 SE n=3 Ki 29.5 ± 3.8 SE n=3			
AEA	Seltzman et al., 1997; [^{3}H]CP, [^{3}H]SR, nativeB, +PMSF		[^{3}H]CP: 25 ± 8 SE [^{3}H]SR: 282 ± 42 SE all n=4			
AEA	Sheskin et al., 1997; [^{3}H]HU, nativeB, ØPMSF, Centri		39.2 ± 5.7 S? n=?			
AEA	Adams et al., 1998; [^{3}H]CP, nativeF, +PMSF, ØPMSF,		+PMSF: 2320 ± 540 SE n=6 ØPMSF: 8030 ± 1110			

	Sect		SE n=3			
AEA	Berglund et al., 1998; [^{3}H]CP, *Rn*CB1nativeA, *Hs*CB2nativeL, +PMSF		12 or 13 (says both) ØS? n=?	65 or 67 (says both) ØSE n=?		
AEA	Bonhaus et al., 1998 [^{3}H]CP, trans2, ØPMSF, Log	631 ± 147 SE n=6				
AEA	Edgemond et al., 1998 [^{3}H]CP, nativeD, trans2, +PMSF		107 ± 54 SE n=3	94 ± 9 SE n=3		
AEA	Lin et al., 1998; [^{3}H]CP, CB1nativeC, +PMSF, ØPMSF		+PMSF: 61.0 ±4.2 SE ØPMSF: 5810 ±209.2 SE all n=2			
AEA	Tao & Abood, 1998 [^{3}H]CP, trans4 +PMSF	321 ± 85 SE n=3				
AEA	Thomas et al., 1998 [^{3}H]CP, nativeB, +PMSF, ØPMSF		[^{3}H]CP +PMSF: 29.7 ± 7.49 SE n=4 [^{3}H]CP ØPMSF: 6984 ± 378 SE n=? [^{3}H]SR: 103 ± 10.8 SE n=3			
AEA	Griffin et al., 1999 [^{3}H]SR, nativeD, ØPMSF		170 ± 36.6 SE n~4.5			
AEA	Hillard et al., 1999; [^{3}H]CP, nativeD, nativeJ +PMSF		71.1 ± 7.3 SE n=4		279 ± 58 SE n=3	*Rn 1:2:*0.3 N:N
AEA	Kearn et al., 1999 [^{3}H]CP, [^{3}H]SR, nativeD, +PMSF		[^{3}H]CP:71.7 ± 73 SE [^{3}H]SR: 149 ± 15 SE all n=4			
AEA	Lambert et al., 1999; *Hs*CB1trans2, [^{3}H]SR, ØPMSF *Hs*CB2trans2, [^{3}H]WIN,	>1000 Ø SE n=3		>1000 Ø SE n=3	430 ± 65 SE n~5	*H2:R2:*>2.3 T:N

	ØPMSF *Rn*CB2nativeJ, [^{3}H]CP, +PMSF					
AEA	Song et al., 1999 [^{3}H]CP, trans4, ØPMSF	76.2 ± 11.1 SE n=3		131.2 ± 14.1 SE n=3		*Hs 1:2:*0.6 T:T
AEA	Tao et al., 1999 [^{3}H]CP or [^{3}H]WIN, trans4, ØPMSF			306 ± 48 SE n=3		
AEA	Gonsiorek et al., 2000; [^{3}H]CP, trans2 + trans7, +PMSF			trans2: 348 ± 31 SE n=5 trans7: 795 ± 46 SE n=3		
AEA	Griffin et al., 2000 [wrong rat sequence] [^{3}H]CP, trans4, +PMSF			306 ± 48 SE n=2	>10,000 ØSE n=2	*H2:R2:*0.03 T:T
AEA	Melck et al., 2000; [^{3}H]SR, native T47D, MCF7, DU145 breast carcinoma cells ØPMSF	T47D:1500 ± 310 SD MCF7: 850 ± 250 SD DU145: 160 ± 19 SD all n=3				
AEA	Bisogno et al., 2000 [^{3}H]SR, nativeA, nativeJ +PMSF		800 ± S? n=?		2400 ± S? n=?	*Rn* 1:2:0.3 N:N
AEA	Bezuglov et al., 2001 [^{3}H]SR, nativeB, +PMSF		800 ± ?S n=?			
AEA	DiMarzo et al., 2001 [^{3}H]SR, nativeA, ØPMSF		800 ± 200 SD n=3			
AEA	Feng + Song, 2001 [^{3}H]HU, trans4, ØPMSF			314.5 ± 64.8 SE n=3		
AEA	Fowler et al., 2001; [^{3}H]SR, nativeB, ØPMSF but "low membrane concentration"		240 ± 245 SE n~2.5			
AEA	McAllister et al., 2002 [^{3}H]CP, trans4, +PMSF	450 ± 226 SE n=3		188 ± 176 SE n=3		*Hs 1:2:*2.4 T:T

AEA	Song + Feng, 2002 [^{3}H]WIN, trans4, ØPMSF			687 ± 176 SE n=3		
AEA	van der Stelt et al., 2002 [^{3}H]CP, nativeC+J, +PMSF		90 ±20 S? n=?		360 ± 50 S? n=?	*Rn 1:2:*0.36 N:N
AEA	Feng & Song, 2003 [^{3}H]HU, trans4, ØPMSF			(cited Feng and Song, 2001)		
AEA	Leggett et al., 2004; [^{3}H]CP, nativeB ØPMSF "Kd from review"		428 ± 82 SE n=3			
AEA	Mukherjee et al., 2004 [^{3}H]CP, trans4, +PMSF			160 ± 63.8 SE n=4	240 ± 33.2 SE n=4	*H2:R2:*0.7 T:T
AEA	Steffens et al., 2004; [^{3}H]CP, nativeC, nativeAmygdala, +PMSF	nativeD +PMSF: 25.7 ± 3.3 SE nativeD ØPMSF: 209 ± 27 SE amygdala +PMSF: 54.0 ± 7.2 SE amygdala ØPMSF: 182 ± 27 SE all n=3				
AEA	Bobrov et al., 2005 [^{3}H]CP HsCB1+2 trans2, RnCB1+2 nativeC+nativeJ, ØPMSF	240 ± ? Sn=2	160 ± ?S n=2	290 ± ?S n=2	3000 ± ?S n=2	*H1:R1:*1.5 T:N *H2:R2:*0.1 T:N *Hs 1:2:*0.83 T:T *Rn 1:2:*0.05 N:N
AEA	Brizzi et al., 2005 [^{3}H]CP, trans3, +PMSF	72 ± 3.1 SE n=3				
AEA	Ryberg et al., 2005 [^{3}H]CP, trans4, ØPMSF	24.4 ± 2.0 SE n=5				
AEA	Savinainen et al., 2005 [^{3}H]CP, trans2, ØPMSF, Log			5100 ± 1185 SE n=3		
AEA	Appendino et al., 2006 [^{3}H]CP, trans3, +PMSF	70 ± 0.10 SE n=3		180 ± 0.20 S? n=?		*Hs 1:2:*0.4 T:T
AEA	D'Antona et al., 2006	[^{3}H]CP: 26.0 ± 0.1 SE [^{3}H]SR:189 ± 4 SE				

	[^{3}H]CP, [^{3}H]SR, trans4, +PMS	all n=3				
AEA	Raduner et al., 2006; [^{3}H]CP trans4 ØPMSF	37 Ø SD n=3		218 ±149 SD n=3		*Hs 1:2*:0.2 T:T
metA	Abadji et al., 1994 ^{3}H]CP, nativeC, +PMSF		20 ± 1.6 SE n=3			
metA	Adams et al., 1995 [^{3}H]CP, nativeB ØPMSF		87 ± 18 SE n~4.5			
metA	Khanolkar et al., 1996 [^{3}H]CP, nativeC +PMSF		(cited Abadji et al., 1994)		see *Mm* data	
metA	Sheskin et al., 1997; [^{3}H]HU, nativeB, ØPMSF, Centri		31.1 ± 1.0 S? n=?			
metA	Berglund et al., 1998, [^{3}H]CP, *Rn*CB1nativeA, *Hs*CB2nativeL +PMSF		3.2 Ø S? n=?	26 Ø S? n=?		
metA	Lin et al., 1998; [^{3}H]CP, CB1nativeC, +PMSF		17.9 ± 0.89 SE n=2			
metA	Chin et al., 1999; [^{3}H]CP trans2, ØPMSF	35 ± 0.2 SE n=2		(cited Khanolkar et al., 1996)		
metA	Lambert et al., 1999; *Rn*CB2nativeJ, [^{3}H]CP, +PMSF				>1000 Ø SE n~5	
metA	Breivogel & Childers, 2000 [^{3}H]SR, nativeD, nativeE, native hypothalamus		nativeD: 150 ± 10 SE nativeE: 330 ± 46 SE hypothal: 240 ± 51 SE all n=4			
metA	D'Antona et al., 2006 [^{3}H]CP, [^{3}H]SR, trans4, +PMS	[^{3}H]CP:630 ± 1 SE [^{3}H]SR: 6960 ± 2230 SE all n=3				
2AG	Mechoulam et al., 1995; [^{3}H]HU, trans3, ØPMSF,		472 ± 55 SE n=3	1400 ± 172 SE n=3		

	Centri					
2AG	Sugiura et al., 1995 [^{3}H]CP, nativeC, +DPFP		2400 Ø SD n=4			
2AG	Ben-Shabat et al., 1998; [^{3}H]HU, trans2+3, ØPMSF, Centri			trans2: 1640 ± 260 SE trans3: 145 ± 39 SE all n=?		
2AG	Gonsiorek et al., 2000; [^{3}H]CP, trans2 + trans7, +PMSF			trans2: 474 ± 92 SE n=5 trans7: 949 ± 270 SE n=3		
2AG	van der Stelt et al., 2002 [^{3}H]CP, nativeC+J, +PMSF		100 ± 20 S? n=?		100 ± 20 S? n=?	*Rn 1:2:*1.0 N:N
2AG	Mukherjee et al., 2004 [^{3}H]CP, trans4, +PMSF			1100 ± 71.4 SE n=4	3700 ± 2500 SE n=4	*H2:R2:*0.3 T:T
2AG	Bobrov et al., 2005 [^{3}H]CP *Hs*CB1+2 trans2, *Rn*CB1+2 nativeC+nativeJ, ØPMSF	160 ± ?S n=2	26% @ 1 µM n=2	520 ±?S n=2	37% @ 1 µM n=2	*Hs 1:2:*0.31 T:T
2AG	Ryberg et al., 2005 [^{3}H]CP, trans4, ØPMSF	110.7 ± 19.6 SE n=5				
2AG	Savinainen et al., 2005 [^{3}H]CP, trans2, ØPMSF			3500 ± 814 SE n=3		
2AG	Shoemaker et al., 2005(2005); [^{3}H]CP, CB1nativeD, CB2trans2, +PMSF		1750 ± 358 SE n~6	1016 ± 170 SE n~6		
2AG	Steffens et al., 2005 [^{3}H]CP, nativeC, +PMSF	>10000 ØSD n=3				
CP	Devane et al., 1988; [^{3}H]CP, nativeC, Centri		Kd 0.133 ± 0.006 SE n=3 Ki 0.068 ± 0.006 SE n=3			

CP	Bidaut-Russell et al., 1990 [^{3}H]CP, native, mean of 7 brain regions, Centri		Kd 0.119 ± 0.049 SE n=3			
CP	Bridgen et al., 1990 [^{3}H]CP, nativeC		0.78 ØSE n=?			
CP	Herkenham et al., 1990; [^{3}H]CP, nativeA, Sect		Kd 15 ± 3 SD n=?			
CP	Gérard et al., 1991 [^{3}H]CP, trans3	Kd 1.0 ØSE n=?				
CP	Houston et al., 1991 [^{3}H]CP, nativeC		Kd 0.950 ØSE n=?			
CP	Martin et al., 1991 [^{3}H]CP, nativeB,		0.7 ØSE n=?			
CP	Devane et al., 1992; [^{3}H]HU, nativeB, Centri		2.0 ± 0.5 SE n=3			
CP	Felder et al., 1992 [^{3}H]CP *Hs*CB1trans5, *Rn*CB1 nativeD, trans2	Kd 3.3 ± 0.7 SE n=3 Ki 3.7 ± 0.1 SE n=3	trans2: Kd 4.0 ± 0.9 SE n=? nativeD Kd 2.3 ± 0.4 SE n=?			*H1:R1:*0.8 T:T
CP	Houston & Howlett, 1992; [^{3}H]CP, nativeC, membrane or CHAPS-solubilized receptor		membrane Kd: 0.939 ØSE n=? + CHAPS Kd: 0.944 ØSE n=?			
CP	Jansen et al., 1992; [^{3}H]WIN, nativeD, Sect		1.0 ± 0.1 SE n=3			
CP	Thomas et al., 1992; [^{3}H]THC-DMH, nativeF, Sect		Kd 19 ± 3 SE n=6 Ki 52 ± 5.4 SE n=3			
CP	Bouaboula et al., 1993 [^{3}H]CP, nativeH			Kd 0.093 ± 0.024 S? n=2 Ki 0.062 ± 0.008 S? n=2		
CP	Compton et al., 1993		Kd 0.924 ± 0.14 SE			

	[^{3}H]CP, nativeC		n~4.5 “true” Kd 0.675 ØSE n=?			
CP	Houston & Howlett, 1993 [^{3}H]CP, nativeC		Kd 0.94 ± 0.1 SE n=3			
CP	Lu et al., 1993 [^{3}H]CP, nativeC		Kd 1.48 ± 0.02 SE n~4.5			
CP	Melvin et al., 1993 [^{3}H]CP, nativeB, Centri		1.14 ± 0.04 SE n=3			
CP	Munro et al., 1993 [^{3}H]CP, trans3, Centri			Kd 1.6 ± 0.5 S? n=4		
CP	Oviedo et al., 1993; [^{3}H]CP, nativeA, Sect		Kd 22.23 ± 1.07 SE n=6			
CP	Koutek et al., 1994 [^{3}H]CP, nativeB		0.35 ØSE n=5			
CP	Lynn + Herkenham, 1994; [^{3}H]CP, nativeJ, Sect		(cited Herkenham et al., 1990)		7.2 ± 2.4 SD n=2	
CP	McLaughlin et al., 1993 [^{3}H]CP, nativeC		Kd 0.696 ± 0.076 SE n=15			
CP	Pettit et al., 1994 [^{3}H]CP, trans7		Kd 3.4 ØSE n=7			
CP	Rodríguez de Fonseca et al., 1993 [^{3}H]CP, limbic forebrain		male Kd 0.67 ± 0.07 SE n~6.5 female Kd 1.04 ± 0.07 SE n~6.5			
CP	Rinaldi-Carmona et al., 1994 [^{3}H]CP, CB1nativeC, CB2nativeJ		1.37 ± 0.43 SE n=4		1.37 ± 0.38 SE n=3	*Rn 1:2:*1.0 N:N
CP	Rodríguez de Fonseca et al., 1994; [^{3}H]CP, native striatum, limbic forebrain, midbrain		striatum Kd: 0.94 ± 0.16 SE limbic Kd: 0.80 ± 0.08 SE midbrain Kd: 0.84 ± 0.22 SE			

			all n=6			
CP	Rodríguez de Fonseca et al., 1994; [^{3}H]CP, native striatum, limbic forebrain, midbrain		male mean Kd: 0.77 ± 0.077 SE Female mean Kd: 1.05 ± 0.077 SE all n=7			
CP	Adams et al., 1995 [^{3}H]CP, nativeB, +PMSF, ØPMSF		ØPMSF Kd 0.58 ± 0.07 SE n=5 +PMSF Kd 1.03 ± 0.13 SE n=3			
CP	Belue et al., 1995 [^{3}H]CP, nativeB, adults Centri		Kd 0.55 ± 0.33 SE n=4			
CP	Bouaboula et al., 1995 [^{3}H]CP, trans2	0.68 ± 0.1 SE n=?				
CP	Bouaboula et al., 1995; [^{3}H]CP, native U373 astrocytoma cell	Kd 0.54 ± 0.07 SE n=2 Ki 3.86 ± 1.28 SE n=2				
CP	Felder et al., 1995 [^{3}H]CP *Hs*CB1trans5, *Hs*CB2trans1, *Rn*CB2 trans1, trans2, nativeJ	(cited Felder et al., 1992)		2.55 ± 0.19 SE n=3	trans1 Kd 6.94 ± 4.6 SD n=2 trans2 Kd 7.37 ± 1.9 SD n=2 nativeJ Kd 0.18 ± 0.0035 SD n=2	*H2R2:*0.37 T:T *Hs 1:2:*1.5 T:T
CP	Hillard et al., 1995 [^{3}H]CP, nativeC, +PMSF, ØPMSF		ØPMSF Kd 0.5 ± 0.07 SE n=5 +PMSF Kd 0.7 ± 0.1 SE n=5			
CP	Romero et al., 1995; [^{3}H]CP, nativeD, nativeE, striatum		nativeD Kd: 0.73 ± 0.10 SE nativeE Kd: 0.91 ± 0.07 SE striatum Kd: 1.09 ± 0.18 SE all n=7			
CP	Slipetz et al., 1995			1.0 ± 0.2 SE n~5		

	[^{3}H]WIN, trans3					
CP	Sugiura et al., 1995 [^{3}H]CP, nativeC		Kd 0.83 ± 0.06 SD n=3			
CP	Welch et al., 1995; [^{3}H]CP, native spinal cord		Kd 0.90 ± 0.2 SE n=3			
CP	Bouaboula et al., 1996 [^{3}H]CP, trans2			4 ± 0.7 SE n=?		
CP	Rinaldi-Carmona et al., 1996 [^{3}H]SR, nativeB		8.1 ± 2.41 SE n=3			
CP	Rinaldi-Carmona et al., 1996 [^{3}H]CP, trans2	Kd 1.39 ± 0.15 SE n=3 Ki 2.26 ± 0.6 SE n=3				
CP	Shire et al., 1996 [^{3}H]CP, trans3			2.4 ± 0.64 SE n=4		
CP	Shire et al., 1996 [^{3}H]CP, trans3	Kd 0.4 ± 0.09 SE n~4		Kd 0.2 ± 0.07 SE n~4		*Hs 1:2:*2.0 T:T
CP	Showalter et al., 1996 [^{3}H]CP, trans2, +PMSF, ØPMSF	0.58 ±0.07 SE n~4		ØPMSF Kd 0.61 ± 0.014 SE n=4 ØPMSF Ki 0.69 ± 0.02 SE n~4 +PMSF Kd 0.985 ± 0.046 SE n=4		*Hs 1:2:*0.8 T:T
CP	Song & Bonner, 1996 [^{3}H]WIN, trans4	4.6 ± 1.2 SE n=3				
CP	Deutsch et al., 1997; [^{3}H]AEA, native renal endothelium		28.1 ± 3.3 SE n=3			
CP	Jung et al., 1997; [^{3}H]SR, nativeC		31.9 Ø SE n=4			
CP	Adams et al., 1998; [^{3}H]CP, nativeF, +PMSF, ØPMSF, Sect		ØPMSF Kd 15.3 ± 1.2 SE n=5 +PMSF: Kd 12.3 ± 2.1 SE n=3			
CP	Bonhaus et al., 1998	3 ± 1 SE n=6				

	[^{3}H]CP, trans2					
CP	Chin et al., 1998 [^{3}H]CP, trans2	Kd 7.7 ± 3.5 SE n=3				
CP	Houston & Howlett, 1998 [^{3}H]CP, nativeC		Kd 1.97 ± 0.66 SE n=3			
CP	Lin et al., 1998; [^{3}H]CP, CB1nativeC		Kd 0.85 Ø SE, n=?			
CP	MacLennan et al., 1998 [^{3}H]CP, trans2	Kd 2.8 ± 0.8 SE n=5 Ki 2 ± 0.5 SE n=5		Kd 4.7 ± 1.8 SE n=5 Ki 2 ± 0.25 SE n=5		*Hs 1:2:*1.0 T:T
CP	Nowell et al., 1998 [^{3}H]CP, trans7			Kd 2.24 ± 0.76 SE n=3		
CP	Rinaldi-Carmona et al., 1998 [^{3}H]CP, [^{3}H]SR, trans2	[^{3}H]CP Kd 5.47 ± 0.28 SE n=13 [^{3}H]CP Ki 16.9 ± 1.1 SE n=7 [^{3}H]SR Ki 39.2 ± 5.6 SE n=6				
CP	Tao & Abood, 1998 [^{3}H]CP trans4	Kd 1.21 ± 0.28 SE n=3		0.88 ± 0.09 SE n=3		*Hs 1:2:*1.4 T:T
CP	Thomas et al., 1998 [^{3}H]CP, [^{3}H]SR, nativeB		[^{3}H]CP Kd 0.72 ± 0.02 SE n=3 [^{3}H]CP Ki 0.54 ± 0.03 SE n=3 [^{3}H]SR Ki 20.7 ± 4.83 SE n=6			
CP	Abadji et al., 1999 [^{3}H]CP, trans2,	Kd 7.7 ± 3.5 SE n=2				
CP	Chin et al., 1999 [^{3}H]CP, trans2	Kd 3.8 ± 0.8 SE n=2		4.2 ± 0.8 SE n=2		*Hs 1:2:*0.9 T:T
CP	Griffin et al., 1999 [^{3}H]SR, nativeD		4.8 ± 1.06 SE n~4.5			
CP	Griffin et al., 1999 [^{3}H]CP, trans4, nativeB, nativeD		nativeB Kd 1.45 ± 0.95 SE n~5 nativeD Kd 1.08 ±	trans4 Kd 1.11 ± 0.09 SE n~5		

			0.01 SE n~5			
CP	Hillard et al., 1999 [^{3}H]CP, nativeD, nativeJ		Kd 0.5 ± 0.1 SE n=4		2.8 ± 0.4 SE n=4	*Rn 1:2:*0.2 N:N
CP	Kathmann et al., 1999 [^{3}H]SR, nativeC, Log		45.7 ± 8.5 SE n=4			
CP	Kearn et al., 1999 [^{3}H]CP, [^{3}H]SR, nativeD		[^{3}H]CP Kd 0.52 ± 0.08 SE n=3 [^{3}H]CP Ki 0.58 ± 0.1 SE n=4 [^{3}H]SR Ki 4.3 ± 1.3 SE n=4			
CP	Kanyonyo et al., 1999 [^{3}H]SR, trans2	5.2 ± 0.3 SE n~4				
CP	Lambert et al., 1999; trans2, CB1: [^{3}H]SR, CB2: [^{3}H]WIN	5.16 ± 0.27 SE n~5		19.8 ± 1.6 SE n=3		
CP	Ross et al., 1999 [^{3}H]CP, trans2	Kd 1.2 ØS? n=? Ki 5.0 ± 0.8 S? n~3.5		Kd 0.8 ØS? n=? Ki 1.8 ± 0.2 S? n~3.5		*Hs 1:2:*2.8 T:T
CP	Ross et al., 1999 [^{3}H]CP, trans2	Kd 1.62 S? n=? 4 ± 0.5 S? n=4		Kd 0.99 S? n=? Ki 7 ± 1 S?n=4		*Hs 1:2:*1.6 T:T *Hs 1:2:*0.6 T:T
CP	Song et al., 1999 [^{3}H]CP, trans4	2.2 ± 0.3 SE n=3		2.4 ± 0.4 SE n=3		*Hs 1:2:*0.9 T:T
CP	Tao et al., 1999 [^{3}H]CP or [^{3}H]WIN, trans4			Kd 0.88 ± 0.09 SE n=3 Ki 0.75 ± 0.08 SE n=3		
CP	Breivogel + Childers, 2000 [^{3}H]SR, nativeD, nativeE, native hypothalamus		nativeD: 1.7 ± 0.5 SE nativeE: 5.6 ± 1.4 SE hypothal: 2.0 ± 1.1 SE all n=4			
CP	Griffin et al., 2000 [wrong rat sequence] [^{3}H]CP, trans4			(cited Tao et al., 1999)	0.64 ± 0.06 SE n=2	
CP	Meschler et al., 2000 [^{3}H]CP, nativeC		Kd 0.35 ØSE n=?			
CP	Rhee et al., 2000 [^{3}H]HU, trans3, Centri			5.9 ± 1.0 SE n=3		

CP	Fowler et al., 2001 [^{3}H]SR, nativeB		8.44 ± 2.4 SE n~2.5			
CP	Iwamura et al., 2001 [^{3}H]CP, *Hs*CB1+CB2 trans2, *Rn*CB1+CB2 nativeD+nativeK	Kd 0.57 ØSE n=?	Kd 0.23 ØSE n=?	Kd 0.23 ØSE n=?	Kd 0.70 ØSE n=?	*H1:R1:*2.5 T:N *H2:R2:*0.3 T:N *Hs 1:2:*2.5 T:T *Rn 1:2:*0.3 N:N
CP	Devlin+Christopoulos, 2002 [^{3}H]SR, nativeD, Log		1.26 ±0.94 SE n=6			
CP	Ho et al., 2002 [^{3}H]CP, trans3	0.58 ± 0.11 SE n=6		0.67 ± 0.15 SE n=5		*Hs 1:2:*0.9 T:T
CP	Mauler et al., 2002; [^{3}H]BAY, *Hs*CB1trans0, *Hs*CB1nativeC, *Rn*CB1nativeC, *Hs*CB2trans0,	nativeC: 0.51 ± 0.03 SD trans0: 1.10 ± 0.20 SD all n=3	1.30 ± 0.29 SD n=3	0.52 ± 0.13 SD n=3		*H1:R1:*0.4 N:N *H1:R1:*0.9 T:N *Hs 1:2:*1.0 N:T 2.1 T:T
CP	McAllister et al., 2002 [^{3}H]CP, trans4	Kd 5.2 ± 1.7 SE n=3		Kd 0.60 ± 0.31 SE n=3		*Hs 1:2:*8.7 T:T
CP	Ooms et al., 2002 [^{3}H]SR, trans2	5.2 ± 0.3 SE n=3				
CP	van der Stelt et al., 2002 [^{3}H]CP, nativeC+J, +PMSF		Kd 0.8 ± 0.2 S? n=?		Kd 0.2 ± 0.1 S? n=?	*Rn 1:2:*4.0 N:N
CP	Breivogel et al., 2003; [^{3}H]CP, nativeD		Kd 0.34 ± 0.05 SE n=3			
CP	Marchese et al., 2003; [^{3}H]CP, nativeD		Kd 0.32 ± 0.05 SE n=?			
CP	Murphy+Kendall, 2003 [^{3}H]CP, [^{3}H]SR, trans4	[^{3}H]CP Kd 4.6 ± 0.6 SE [^{3}H]SR Kd 8.3 ± 1.1 SE all n=2				
CP	Andersson et al., 2003 [^{3}H]CP, trans4	[^{3}H]CP Kd (cited Murphy and				

		Kendall, 2003)				
CP	De Vry et al., 2004; [^{3}H]BAY, CB1nativeC, CB2trans0	(cited Mauler et al., 2002)	1.15 ± 0.06 SD n=3	0.54 ± 0.10 SD n=3		
CP	Govaerts et al., 2004a *Hs*CB1trans2 - [^{3}H]CP; *Rn*CB1trans2 - [^{3}H]SR; *Rn*CB2 nativeJ - [^{3}H]CP	Kd 4.73 ± 1.32 SE n~5	2.4 ± 4.7 SE n~5		Kd 2.2 ± 0.4 SE n~5	*Rn* 1:2:1.1 N:N
CP	Govaerts et al., 2004b *Hs*CB1 trans2 - [^{3}H]CP; *Hs*CB2 trans2 - [^{3}H]WIN; *Rn*CB1 nativeD - [^{3}H]CP; [^{3}H]SR; *Rn*CB2 nativeJ - [^{3}H]CP	Kd (cited Govaerts et al., 2004b) Ki 6.6 ± 0.5 SE all n~5	Kd 2.08 ± 0.32 SE Ki 38 ± 7 SE all n~5	11.2 ± 1.0 SE n~5	Kd 2.18 ± 0.46 SE n~5	*H1:R1:*2.3 T:N *H2:R2:*5.1 T:N *Hs 1:2:*0.42 T:T *Rn 1:2:*1.0 N:N
CP	Hungund et al., 2004 [^{3}H]CP, nativeC	Kd 1.12 ± 0.10 SE n=3				
CP	Mukherjee et al., 2004(2004) [^{3}H]CP, trans4			Kd 0.58 Ø SE n=3 Ki 0.68 ± 0.17 SE n=4	Kd 0.45 Ø SE n=3 Ki 0.52 ± 0.08 SE n=4	*H2:R2:*1.3 T:T
CP	Steffens et al., 2004; [^{3}H]CP, nativeC, nativeAmygdala	nativeD Kd 1.70 ± 0.14 nativeD Ki 2.14 ± 0.19 SE amygdala Kd 1.66 ± 0.16 amygdala Ki 2.29 ± 0.20 SE all n=3				
CP	Bari et al., 2005 [^{3}H]CP, native C6 glioma cells		Kd 0.598 ± 0.086 SD n=3			
CP	Bobrov et al., 2005 [^{3}H]CP *Hs*CB1+2 trans2, *Rn*CB1+2 nativeC+nativeJ	Kd 0.31 ± ?S n=2	Kd 0.09 ± ?S n=2	Kd 0.49 ± ?S n=2	Kd 0.17 ± ?S n=2	*H1:R1:*3.4 T:N *H2:R2:*2.9 T:N *Hs 1:2:*3.4 T:T *Rn 1:2:*0.53 N:N

CP	Dyson et al., 2005 [^{3}H]CP, CB1 trans4, CB2 trans2	0.8 ± 0.1 SE n=3		0.3 ± 0.02 SE n=3		*Hs 1:2:*2.7 T:T
CP	Fay et al., 2005 [^{3}H]CP, trans3	5.5 ± 2.7 SE n=2				
CP	Hill et al., 2005; [^{3}H]CP, nativeE, limbic forebrain (LF), hypo		nativeE Kd 0.45 ± 0.11 SE LF Kd 0.676 ± 0.20 SE all n=4-6			
CP	Hill et al., 2005 [^{3}H]CP, amygdala		Kd 1.0 ± ?S n=3-4			
CP	Picone et al., 2005 [^{3}H]CP, trans2	Kd 6.7 ± 0.34 SE n=3				
CP	Ryberg et al., 2005 [^{3}H]CP, trans4	Kd 1.43 Ø SE, n=? Ki 2.53 ± 0.3 SE n=5				
CP	Savinainen et al., 2005 [^{3}H]CP, trans2			Kd (mean of two clones) 4.6 ± 0.9 SE n=3 Ki 1.34 ± 0.37 SE n=3		
CP	Shoemaker et al., 2005 [^{3}H]CP, CB1nativeD, CB2trans2		Kd 0.55 ± 0.17 SE n~6	Kd 0.38 ± 0.03 n=4 Ki 0.58 ± 0.09 SE n~6		
CP	Valenzano et al., 2005 [^{3}H]CP, *Hs*CB1+CB2 trans2 *Rn*CB1 nativeC, *Rn*CB2 nativeJ	Kd 1.37 ± 0.46 SE n=3 Ki 2.84 ± 0.64 SE n=3	Kd 1.27± 0.03 SE n=3	Kd 1.43 ± 0.79 SE n=3 Ki 2.33 ± 0.50 SE n=3	Kd 0.60 ± 0.12 SE n=3	*H1:R1:*1.1 T:N *H2:R2:*2.4 T:N *Hs 1:2:*0.96 T:T *Rn 1:2:*2.1 N:N
CP	Vinod et al., 2005 [^{3}H]CP, nativeC	Kd 1.3 ± 0.3 SD n=22				
CP	D'Antona et al., 2006 [^{3}H]CP, [^{3}H]SR, trans4	Kd 4.6 ± 0.6 SE [^{3}H]SR Ki 8.1 ± 0.9 SE all n=3				
CP	Hill et al., 2006; [^{3}H]CP,		nativeE Kd 1.14 ± 0.014;			

	nativeE, prefrontal cortex, hypothalamus, amygdala		prefrontal cortex Kd 0.27 ± 0.04; hypothalamus Kd 2.21 ± 0.1.24; amygdala Kd 1.7 ± 0.86; all n~3.5, SE			
CP	Lunn et al., 2006 [^{3}H]CP, trans7			1.0 ± 0.3 SE n=2		
CP	Martin et al., 2006; [^{3}H]CP, *Rn*CB1 nativeA, *Hs*CB2 trans2		Kd 4.0 ± 0.3 SE n=3	Kd 2.5 ± 0.1 SE n=3		
CP	Nebane et al., 2006 [^{3}H]CP, trans4	Kd 1.36 ± 0.92 n=3		Kd 0.83 ± 1.04 n=3		*Hs 1:2:*1.64 T:T
CP	Shen et al., 2006 [^{3}H]CP, trans2	0.047 ± 0.003 SE n=3				
WIN	Haycock et al., 1990 [^{3}H]WIN, nativeD		Kd 2 Ø SE n=?			
WIN	D'Ambra et al., 1992 [^{3}H]WIN, nativeD		Kd 2 Ø SE n=3 Ki 4.45 ± 0.33 SE n=?			
WIN	Felder et al., 1992 [^{3}H]CP, CB1trans5	564 ± 12.5 SE n=3				
WIN	Jansen et al., 1992; [^{3}H]WIN, nativeD, Sect		Kd 15.0 ± 4.12 SE n=8 Ki 8.8 ± 0.4 SE n=3			
WIN	Thomas et al., 1992; [^{3}H]THC-DMH, nativeF, Sect		322 ± 108 SE n=3			
WIN	Bouaboula et al., 1993 [^{3}H]CP, nativeH			16.14 ± 1.27 S? n=2		
WIN	Kuster et al., 1993 [^{3}H]WIN, nativeD		Kd 1.89 ± 0.091 SE n=3 Ki 2.2 ± 0.26 SE n=3			

WIN	Munro et al., 1993 [^{3}H]CP, trans3			3.7 ± 0.4 S? n=4		
WIN	Childers et al., 1994 [^{3}H]WIN, nativeD		0.30 ± 0.06 S? n=3			
WIN	Rinaldi-Carmona et al., 1994 [^{3}H]CP, CB1nativeC, CB2nativeJ		9.94 ± 1.04 SE n=4		16.2 ± 5.5 SE n=3	*Rn 1:2:*0.6 N:N
WIN	Bouabola et al., 1995 [^{3}H]CP, trans2	485 ± 63 SE n=?				
WIN	Bouaboula et al., 1995; [^{3}H]CP, native U373 astrocytoma cell	97.6 ± 124 SE n=2				
WIN	Facci et al., 1995 [^{3}H]WIN, nativeN,				Kd 33.5 ± 6.0 SE n=3	
WIN	Felder et al., 1995 [^{3}H]CP CB1trans5, CB2trans1	62.3 ± 31 SE n=3		3.30 ± 0.40 SE n=3		*Hs 1:2:* 18.9 T:T
WIN	Slipetz et al., 1995 [^{3}H]WIN, trans3			Kd trans3 2.1 ± 0.2 n=3 Kd trans2 3.8 Ø SE n=? Ki trans3 1.3 ±0.2 SE n~5		
WIN	Bouabola et al., 1996 [^{3}H]CP, trans2			22 ± 1.6 SE n=?		
WIN	Hirst et al., 1996 [^{3}H]SR, nativeD		18 ± 6 SE n=5			
WIN	Petitet et al., 1996 [^{3}H]SR, [^{3}H]WIN, nativeD		Kd 1.1 ± 0.1 SE n~5 [^{3}H]SR Ki 28 ± 13 SE n~5			
WIN	Rinaldi-Carmona et al., 1996 [^{3}H]SR, nativeB		39.4 ± 1.15 SE n=3			
WIN	Rinaldi-Carmona et al., 1996 [^{3}H]CP, trans2	93 ± 13.5 SE n=3				

WIN	Shire et al., 1996 [^{3}H]CP, trans3			3.7 ± 1.2 SE n=4		
WIN	Showalter et al., 1996 [^{3}H]CP, trans2		(cited Kuster et al., 1993)	0.28 ± 0.16 SE n~4		
WIN	Song + Bonner, 1996 [^{3}H]WIN, trans4	Kd 11.9 ± 1.9 SE n=3				
WIN	Breivogel et al., 1997; [^{3}H]WIN, nativeC,D,E (other brain sections also compared)		nativeC Kd 4.58 ± 1.39 SE nativeD Kd 4.67 ± 0.58 SE native E Kd 2.76 ± 0.25 SE all n=3			
WIN	Deutsch et al., 1997; [^{3}H]AEA, native renal endothelium		41.6 ± 5.2 SE n=3			
WIN	Dutta et al., 1997 [^{3}H]CP, nativeC		8.7 ± 0.1 S? n = ?			
WIN	Gifford et al., 1997 [^{3}H]SR, nativeE		170 ± ? n=?			
WIN	Jung et al., 1997; [^{3}H]SR, nativeC		759 Ø SE n=4			
WIN	Bonhaus et al., 1998 [^{3}H]CP, trans2	32 ± 33 SE n=6				
WIN	Chin et al., 1998 [^{3}H]WIN, trans2	Kd 16.2 ± 7.4 SE n=2				
WIN	Edgemond et al., 1998 [^{3}H]CP, nativeD, trans2, +PMSF		2.8 ±1.7 SE n=3	1.6 ØSE n=3		
WIN	Houston + Howlett, 1998 [^{3}H]SR, nativeC		membrane:1.29 Ø SE +CHAPS: 0.19 Ø SE all n=3			
WIN	MacLennan et al., 1998;	42 ±7 SE n=5		2 ± 0.25 SE n=5		*Hs 1:2:*21.0 T:T

	[^{3}H]CP, trans2					
WIN	Nowell et al., 1998 [^{3}H]CP, trans7			7.15 ± 2.63 SE n=4		
WIN	Reggio et al., 1998(Reggio et al., 1998) [^{3}H]CP, nativeB		(cited Thomas et al., 1998)		(cited Showalter et al., 1996)	
WIN	Shim et al., 1998 [^{3}H]CP, nativeC		0.91± ?S			
WIN	Tao + Abood, 1998 [^{3}H]CP, trans4	17.4 ± 6.2 SE n=3		0.14 ± 0.01 SE n=3		*Hs 1:2:*124.3 T:T
WIN	Thomas et al., 1998 [^{3}H]CP, [^{3}H]SR, nativeB		[^{3}H]CP 2.48 ± 0.29 SE n=3 [^{3}H]SR 21.8 ± 6.06 SE n=4			
WIN	Chin et al., 1999; [^{3}H]WIN, trans2, trans4	trans2 Kd 21.7 ± 6.9 SE n=2 trans4 Kd 20.4 ± 3.6 SE n=4		Kd 2.3 ± 0.2 SE n=2		*Hs 1:2:*9.4 T:T
WIN	Griffin et al., 1999 [^{3}H]SR, nativeD		11.1 ± 3.77 SE n~4.5			
WIN	Hillard et al., 1999; [^{3}H]CP, nativeD, nativeJ		4.4 ± 1.3 SE n=3		1.2 ± 0.25 SE n=3	*Rn 1:2:*3.7 N:N
WIN	Kathmann et al.,1999 [^{3}H]SR, nativeC, Log		1175 ± 273 SE n=4			
WIN	Kearn et al., 1999 [^{3}H]CP, [^{3}H]SR, nativeD		[^{3}H]CP 4.4 ± 1.3 SE n=3 [^{3}H]SR 64.0 ± 29 SE n=4			
WIN	Kanyonyo et al.,1999 [^{3}H]SR, trans2	152.2 ± 9.3 SE n~4				
WIN	Lambert et al., 1999 trans2, [^{3}H]WIN			Kd 10.2 ± 0.72 SE n=3	37 ± 8 SE n~5	*H2:R2:*0.3 T:N
WIN	Roche et al., 1999 [^{3}H]WIN, trans1		Kd 4.3 ± 2.8 SE n~5			

WIN	Ross et al., 1999 [^{3}H]WIN, trans2			Kd 2.1 Ø SE n=?		
WIN	Song et al., 1999 [^{3}H]WIN, [^{3}H]CP, trans4	Kd 11.9 ± 1.9 SE n=3 [^{3}H]CP Ki 25.4 ± 5.9 SE n=3		Kd 0.76 ± 0.04 SE n=3 [^{3}H]CP Ki 1.6 ± 0.5 SE n=3		*Hs 1:2:*15.9 T:T
WIN	Tao et al., 1999 [^{3}H]CP or [^{3}H]WIN, trans4			0.91 ± 0.14 SE n=3		
WIN	Breivogel & Childers, 2000 [^{3}H]SR, nativeD, nativeE, native hypothalamus		nativeD: 11 ± 3 SE nativeE:29 ± 5 SE hypothalamus: 14 ± 4 SE all n=4			
WIN	Griffin et al., 2000 [wrong rat sequence] [^{3}H]CP, trans4			1.19 ± 0.05 SE n=2	10.4 ± 2.3 SE n=2	*H2:R2:*0.1 T:T
WIN	Rhee et al., 2000; [^{3}H]HU, trans3, Centri			1.0 ± 0.3 SE n=3		
WIN	Rhee et al., 2000; [^{3}H]HU, trans3, Centri			1.0 ± 0.2 SE n=3		
WIN	Feng & Song, 2001 [^{3}H]HU, trans4			3.4 ± 1.0 SE n=3		
WIN	Fowler et al., 2001 [^{3}H]SR, nativeB		194 ± 262 SE n~2.5			
WIN	Iwamura et al., 2001; [^{3}H]CP, *Hs*CB1+CB2 trans2, *Rn*CB1+CB2 nativeD+nativeK	9.87 ± 1.52 SE n=3	0.14 ± 0.07 SE n=3	0.29 ± 0.12 SE n=3	1.30 ± 0.33 SE n=3	*H1:R1:*70.5 T:N *H2:R2:*0.2 T:N *Hs 1:2:*34.0 T:T *Rn 1:2:*0.1 N:N
WIN	Muhammad et al., 2001; [^{3}H]CP, *Hs*CB1 trans4	23.0 ± S? n=?				
WIN	Devlin+Christopoulos, 2002 [^{3}H]SR, nativeD, Log		6.3 ± 1.47 SE n=5			
WIN	Mauler et al., 2002; [^{3}H]BAY,	11.7 ± 7.6 SD n=3	6.87 ± 1.11 SD n=3	0.41 ± 0.31 SD n=3		*H1:R1:*1.7 T:N *Hs 1:2:*28.5 T:T

	*Hs*CB1trans0, *Rn*CB1nativeC, *Hs*CB2trans0					
WIN	McAllister et al., 2002 [^{3}H]CP, trans4	1.3 ± 0.46 SE n=3		1.0 ± 0.26 SE n=3		*Hs 1:2:*1.30 T:T
WIN	Song + Feng, 2002 [^{3}H]WIN, trans4			Kd 4.8 ± 0.4 SE n=3		
WIN	Breivogel et al., 2003; [^{3}H]WIN, nativeD,E,C, and basal ganglia (BG)		nativeD Kd 1.3 ± 0.1 SE nativeE Kd 1.8 ± 0.1 SE nativeC Kd 1.6 ± 0.2 SE BG Kd 1.7 ± 0.1 SE all n~6			
WIN	Govaerts et al., 2004a *Hs*CB1trans2 - [^{3}H]CP; *Rn*CB2 nativeJ - [^{3}H]CP			Kd 12.0 ± 1.3 SE n~5	1.8 ± 0.4 SE n~5	*H2:R2:*6.7 N:N
WIN	Govaerts et al., 2004b *Hs*CB1 trans2 - [^{3}H]CP; *Hs*CB2 trans2 - [^{3}H]WIN; *Rn*CB1 nativeD - [^{3}H]SR; *Rn*CB2 nativeJ - [^{3}H]CP	129 ± 18 SE n~5	282 ± 106 SE n~5	Kd (cited Govaerts et al., 2004b) Ki 17 ± 2 SE all n~5	1.8 ± 2.2 SE n~5	*H1:R1:*0.45 T:N *H2:R2:*6.7 T:N *Hs 1:2:*10.8 T:T *Rn 1:2:*156.7 N:N
WIN	Mukherjee et al., 2004 [^{3}H]CP, trans4			1.2 ± 0.54 SE n=4	2.1 ± 0.87 SE n=4	*H2:R2:*0.6 T:T
WIN	Steffens et al., 2004; [^{3}H]CP, nativeC, native amygdala	nativeC:53.7 ± 1.7 SE amygdala:40.7 ± 6.8 SE all n=3				
WIN	Brizzi et al., 2005 [^{3}H]CP, trans3	21± 1.1 SE n=3		2.1 ± 0.1 SE n=3		*Hs 1:2:*10.0 T:T
WIN	Deng et al., 2005 [^{3}H]CP, nativeB		1.89 Ø SE n=4			
WIN	Muccioli et al., 2005 [^{3}H]SR; trans2	3802 ± 158 SE n=4				

WIN	Picone et al., 2005 [^{3}H]CP, trans2	Kd 18.3 ± 0.99 SE n=3				
WIN	Ryberg et al., 2005 [^{3}H]CP, trans4	13.7 ± 3.4 SE n=5				
WIN	Savinainen et al., 2005 [^{3}H]CP, trans2			3.1 ± 0.76 SE n=3		
WIN	Valenzano et al., 2005 [^{3}H]CP, *Hs*CB1+CB2 trans2	106.9 ± 10.3 SE n=3		2.37 ± 0.40 SE n=3		
WIN	D'Antona et al., 2006 [^{3}H]CP, [^{3}H]SR, trans4	[^{3}H]CP:73 ± 6 SE [^{3}H]SR:68 ± 1 SE all n=3				
WIN	Paugh et al., 2006; [^{3}H]CP, *Hs*CB1trans4, *Hs*CB2trans2,	24.0 ± 10 SE n~3.5	see *Mm* data	1.7 ± 0.23 SE n=4		*Hs 1:2:*14.1 T:T
WIN	Shen et al., 2006 [^{3}H]CP, trans2	1.64 ± 0.18 SE n=3				
HU	Bridgen et al., 1990 [^{3}H]CP, nativeC		0.68 Ø SE n=?			
HU	Devane et al., 1992 [^{3}H]HU, nativeB, Centri		0.181 Ø SE n=3			
HU	Felder et al., 1992 [^{3}H]CP, CB1trans5,	0.06 ± 0.0002 SE n=3				
HU	Compton et al., 1993 [^{3}H]CP, nativeC		0.73 ± 0.11 SE n~4.5			
HU	Bayewitch et al., 1995 [^{3}H]HU, trans2, Centri			0.147 ± 0.007 SE n=?		
HU	Felder et al., 1995; [^{3}H]CP CB1trans5, CB2trans1	0.061 ± 0.007 SE n=3		0.524 ± 0.045 SE n=3		*Hs 1:2:*0.01 T:T
HU	Slipetz et al., 1995 [^{3}H]WIN, trans3			0.36 ± 0.05 SE n~5		
HU	Showalter et al., 1996 [^{3}H]CP, trans2		(cited Compton et al., 1993)	0.22 ± 0.18 SE n~4		

HU	Song + Bonner, 1996 [^{3}H]WIN, trans4	0.26 ± 0.06 SE n=3				
HU	Rhee et al., 1997 [^{3}H]HU, CB1nativeB and trans3, CB2trans3, Centri		nativeB:0.19 ± 0.01 SE trans3: 0.10 ± 0.02 SE all n=3	0.17 ± 0.01 SE n=3		
HU	Bonhaus et al., 1998 [^{3}H]CP, trans2	0.63 ± 0.34 SE n=6				
HU	Tao + Abood, 1998 [^{3}H]CP trans4	0.44 ± 0.16 SE n=3		0.38 ± 0.01 SE n=3		*Hs 1:2:*1.2 T:T
HU	Griffin et al., 1999 [^{3}H]SR, nativeD		0.37 ± 0.12 SE n~4.5			
HU	Kearn et al., 1999 [^{3}H]CP, [^{3}H]SR, nativeD		[^{3}H]CP:0.09 ± 0.01 SE [^{3}H]SR:0.27 ± 0.01 SE all n=4			
HU	Kanyonyo et al., 1999 [^{3}H]SR, trans2	0.82 ± 0.04 SE n~4				
HU	Lambert et al., 1999 [^{3}H]SR, trans2	(cited Kanyonyo et al., 1999)				
HU	Song et al., 1999 [^{3}H]CP, trans4	0.2 ± 0.02 SE n=3		0.19 ± 0.07 SE n=3		*Hs 1:2:*1.1 T:T
HU	Gonsiorek et al., 2000 [^{3}H]CP, trans2 + trans7			trans2 0.83 ± 0.17 SE n=5 trans7 2.3 ± 0.3 SE n=3		
HU	Rhee et al., 2000; [^{3}H]HU, trans3, Centri			0.16 ± 0.07 SE n=3		
HU	Rhee et al., 2000; [^{3}H]HU, trans3, Centri			0.145 ± 0.05 SE n=3		
HU	Feng + Song, 2001 [^{3}H]HU, trans4,			0.47 ± 0.06 SE n=3		
HU	Devlin & Christopoulos, 2002 [^{3}H]SR, nativeD, Log		0.32 ± 0.15 SE n=6			
HU	Mauler et al., 2002;	0.41 ± 0.05 SD n=3	0.39 ± 0.13 SD n=3	0.14 ± 0.11 SD n=3		*H1:R1:*1.1 T:N

	[^{3}H]BAY, *Hs*CB1trans0, *Rn*CB1nativeC, *Hs*CB2trans0					*Hs 1:2:*2.9 T:T
HU	Ooms et al., 2002 [^{3}H]SR, trans2	0.82 ± 0.04 SE n=3				
HU	Song + Feng, 2002 [^{3}H]WIN, trans4			0.62 ± 0.14 SE n=3		
HU	Appendino et al., 2003 [^{3}H]SR, nativeA		4.0 ± 0.3 S? n=3			
HU	Govaerts et al., 2004 *Rn*CB1 nativeD - [^{3}H]SR; *Rn*CB2 nativeJ:[^{3}H]CP		1 ± 0.75 SE n~5		40 ± 14 SE n~5	*Rn* 1:2:0.03 N:N
HU	Govaerts et al., 2004 *Hs*CB1 trans2 - [^{3}H]CP; *Hs*CB2 trans2 - [^{3}H]WIN; *Rn*CB1 nativeD - [^{3}H]SR; *Rn*CB2 nativeJ - [^{3}H]CP	1.7 ± 0.25 SE n~5	2.8 ± 0.9 SE n~5	1.5 ± 1 SE n~5	44.7 ± 24 SE n~5	*H1:R1:*0.6 T:N *H2:R2:*0.02 T:N *Hs 1:2:*1.1 T:T *Rn 1:2:*0.03 N:N
HU	Brizzi et al., 2005 [^{3}H]CP, trans3			0.15 ± 0.03 SE n=3		
HU	Muccioli et al., 2005 [^{3}H]SR; trans2	18.6 ± 1.7 SE n=4				
HU	Ryberg et al., 2005 [^{3}H]CP, trans4	0.15 ± 0.3 SE n=5				
HU	Savinainen et al., 2005 [^{3}H]CP, trans2			1.95 ± 0.75 SE n=3		
HU	D'Antona et al., 2006 [^{3}H]CP, [^{3}H]SR, trans4	[^{3}H]CP:3.4 ± 0.4 SE [^{3}H]SR:6.7 ± 2.3 SE all n=3				
HU	Lunn et al., 2006 [^{3}H]CP, trans7			3.2 Ø SE n=?		
HU	Shen et al., 2006 [^{3}H]CP, trans2	0.025 ± 0.003 SE n=3				

SR	Rinaldi-Carmona et al., 1994 [^{3}H]CP, *Hs*CB1+CB2 trans2, *Rn*CB1+CB2 nativeC+J	5.6 ± 0.5 SE n=4	1.98 ± 0.36 SE n=4	>1000 SE n=4	>1000 SE n=4	*H1:R1:*2.8 T:N *H2:R2:*1.0 T:N *Hs 1:2:*0.006 T:T *Rn* 1:2:0.0 N:N
SR	Bouaboula et al., 1995; [^{3}H]CP, native U373 astrocytoma cell	6.6 ± 1 SE n=2				
SR	Felder et al., 1995 [^{3}H]CP CB1trans5, CB2trans1	11.8 ± 2.0 SE n=3		973 ± 280 SE n=3		*Hs 1:2:*0.02 T:T
SR	Hirst et al., 1996 [^{3}H]SR, nativeD		Kd 0.61± 0.12 SE n=7			
SR	Petitet et al., 1996 [^{3}H]SR, nativeD		Kd 0.59 ± 0.08 SE n=5 Ki 0.89 ± 0.08 SE n~5			
SR	Rinaldi-Carmona et al., 1996 [^{3}H]SR, nativeB		Kd 0.61 ± 0.06 SE n=7 Ki 1.35 ± 0.27 SE n=3			
SR	Rinaldi-Carmona et al., 1996 [^{3}H]CP, trans2	4.9 ± 0.5 SE n=3				
SR	Shire et al., 1996 [^{3}H]CP, trans3			>1000 ØSE n=4		
SR	Showalter et al., 1996 [^{3}H]CP, trans2	12.3 ± 3.1 SE n~4		702 ±62 SE n~4		*Hs 1:2:*0.02 T:T
SR	Breivogel et al., 1997; [^{3}H]SR, native (mean of brain sections)		Kd 0.26 ± 0.03 SE n=3			
SR	Deutsch et al., 1997 ; [^{3}H]AEA, renal endothelium		31.5 ± 4.2 SE n=3			
SR	Gifford et al., 1997 [^{3}H]SR, nativeE		2 ± ? n=?			
SR	Jung et al., 1997; [^{3}H]SR, nativeC		Kd 0.76 ± 0.09 SE n=4			

SR	Felder et al., 1998 [^{3}H]CP CB1trans5, CB2trans2	(cited Felder et al., 1995)		13,200 ± 700 SE n=3		*Hs 1:2:*0.001T:T
SR	Houston + Howlett, 1998 [^{3}H]SR, nativeC		Kd 1.08 ± 0.25 SE n=3			
SR	MacLennan et al., 1998; [^{3}H]CP, trans2, Log	17 ± 3 SE n=5		3020 ± 917 SE n=5		*Hs 1:2:*0.006 T:T
SR	Rinaldi-Carmona et al., 1998 [^{3}H]CP, [^{3}H]SR, trans2	Kd 4.84 ± 0.66 SE n=10 [^{3}H]SR Ki 9.0 ± 1.1 SE n=5 [^{3}H]CP Ki 11.5 ± 1.3 SE n=14				
SR	Tao & Abood, 1998 [^{3}H]CP trans4	0.68 ± 0.12 SE n=3				
SR	Thomas et al., 1998 [^{3}H]CP, [^{3}H]SR, nativeB		Kd 1.20 ± 0.02 SE n=3 [^{3}H]SR Ki 1.18 ± 0.10 SE n=9 [^{3}H]CP Ki 6.18 ± 1.20 SE n=5			
SR	Breivogel et al., 1999 [^{3}H]SR, nativeD,E, striatum		nativeD Kd 0.25 ± 0.007 SE nativeE Kd 0.12 ± 0.002 SE striatum Kd 0.14 ± 0.002 SE all n=?			
SR	Chin et al., 1999 [^{3}H]SR, trans2	Kd 5.9 ± 0.7 SE n=2		(cited Shire et al., 1996b)		
SR	Griffin et al., 1999 [^{3}H]SR, nativeD		0.31 ±0.08 SE n~4.5			
SR	Kanyonyo et al., 1999 [^{3}H]SR, trans2	8.9 ±0.4 SE n~4				
SR	Kathmann et al., 1999; [^{3}H]SR, nativeC,E,striatum		nativeC Kd 2.52 ± 0.1 SE nativeE Kd 3.98 ± 0.1			

			SE striatum Kd 4.26 ± 0.15 SE all n~6			
SR	Kathmann et al., 1999 [^{3}H]SR, nativeC, Log		Kd 1.55 ± 0.10 SE n=4 Ki 2.95 ± 0.83 SE n=4			
SR	Lambert et al., 1999; trans2, CB1: [^{3}H]SR, CB2: [^{3}H]WIN	(cited Kanyonyo et al., 1999)		>1000 Ø SE n=3		
SR	Lan et al., 1999 [^{3}H]CP, nativeB		11.5 ± 1.3 SE n=3			
SR	Meschler et al., 2000 [^{3}H]CP, nativeC		3.1 ± 0.59 SE n=3			
SR	Melck et al., 2000 [^{3}H]SR, native T47D, MCF7, DU145 breast carcinoma cells	T47D: 0.43 ± 0.19 SD MCF7:3.80 ± 1.50 SD DU145:1.26 ± 0.36 SD all n=3				
SR	Fowler et al., 2001 [^{3}H]SR, nativeB		Kd 0.57 ± 0.092 SE n~2.5			
SR	Devlin+Christopoulos, 2002 [^{3}H]SR, nativeD, Log		Kd 1.95 ± 0.21 SE n=3 Ki 2.24 ± 0.68 SE n=3			
SR	Francisco et al., 2002 [^{3}H]SR, [^{3}H]CP, nativeB, trans2		Kd 1.18 ± 0.10 SE Ki 6.18 ± 1.2 SE all n=2	[^{3}H]CP:313 Ø SE n=1		
SR	Hurst et al., 2002 [^{3}H]SR, trans4,	Kd 2.3 ± 1.1 SE n=3				
SR	McAllister et al., 2002 [^{3}H]CP, trans4	7.1 ± 6.36 SE n=3				
SR	Ooms et al., 2002 [^{3}H]SR, trans2	Kd 1.24 ± 0.1 SE n=3 Ki 8.9 ± 0.4 SE n=3				
SR	Shim et al., 2002 [^{3}H]CP, nativeA		1.5 Ø SE n~4.5			
SR	Breivogel et al., 2003		Kd 0.51 ± 0.08 SE n=3			

	[^{3}H]SR, nativeD					
SR	Murphy+Kendall, 2003 [^{3}H]SR, trans4,	Kd 4.7 ± 0.48 SE n=2				
SR	Busch et al., 2004; [^{3}H]SR, native parotid gland		Kd 0.41 ± 0.03 SE n=3			
SR	Govaerts et al., 2004 *Rn*CB1 nativeD - [^{3}H]SR; *Rn*CB2 nativeJ:[^{3}H]CP		Kd 3.12 ± 0.17 SE n~5		1660 ± 192 SE n~5	*Rn* 1:2:0.002 N:N
SR	Govaerts et al., 2004 *Hs*CB1 trans2 - [^{3}H]CP, [^{3}H]SR; *Hs*CB2 trans2 - [^{3}H]WIN; *Rn*CB1 nativeD - [^{3}H]CP, [^{3}H]SR; *Rn*CB2 nativeJ - [^{3}H]CP	Kd: 13.9 ± 1.32 SE Ki: 33.1 ± 13 SE n~5	Kd: 3.1 ± 0.16 SE Ki: 1.2 ± 0.6 SE n~5	2138 ± 753 SE n~5	1622 ± 4309 SE n~5	*H1:R1:* T:N *H2:R2:*1.3 T:N *Hs 1:2:*0.02 T:T *Rn 1:2:*0.000 N:N
SR	Fay et al., 2005 [^{3}H]SR, trans3	Kd 2.8 ± 0.2 SE n=2				
SR	Lang et al., 2005 [^{3}H]CP, trans2	25 ± 15 SE n=3		1580 ±150 SE n=3		*Hs* 1:2:0.016 T:T
SR	Muccioli et al., 2005 [^{3}H]SR; trans2	Kd 1.13 ± 0.13 SE n=3 Ki 5.4 ± 0.2 SE n=4				
SR	Ryberg et al., 2005 [^{3}H]CP, trans4	3.27 ± 0.73 SE n=5				
SR	Thomas et al., 2005 *Hs*CB1 trans2 [^{3}H]CP,SR,WIN *Rn*CB1 nativeB [^{3}H]CP,SR,WIN *Hs*CB1 nativeD with [^{3}H]WIN *Hs*CB2 trans2 with [^{3}H]CP	[^{3}H]CP: 3.92 Ø SE n=1 [^{3}H]SR: 2.43 Ø SE n=1 [^{3}H]WIN: 4.67 Ø SE n=1 nativeD: 3.86 ØSE n=3	[^{3}H]CP + [^{3}H]SR (cited Francisco et al., 2002) [^{3}H]WIN: 1.97 Ø SE n=1	(cited Francisco et al., 2002)		*H1:R1:*0.63 T:T *Hs 1:2:*0.01 T:T

SR	D'Antona et al., 2006 [^{3}H]CP, [^{3}H]SR, trans4	[^{3}H]CP: 7.5 ± 1.6 SE [^{3}H]SR:7.2 ± 1.7 SE all n=3				
SR	Ellis et al., 2006 [^{3}H]SR, trans4	Mean ± Dox ± CYP Kd 0.91 ± 0.13 S? n=?				
SR	Hurst et al., 2006 [^{3}H]SR, trans4, log	Kd 2.3 ± 1.1 SE Ki 1.1 ± 0.23 SE [^{3}H]CP Ki: 7.1 ± 6.4 SE [^{3}H]WIN Ki:18.0 ± 6.3 SE all n~3				
SR	Lunn et al., 2006 [^{3}H]CP, trans7			2596 Ø SE n=?		

[1] Ligands: THC, Δ^9-tetrahydrocannabinol; CBD, cannabidiol; CBN, cannabinol; AEA, anandamide (*N*-arachidonoyl ethanolamine); metA, *R*-(+)-methanandamide; 2AG, *sn*-2 arachidonoyl glycerol; CP, CP55,940; WIN, WIN55212-2; HU, HU210 (11-OH-Δ^8-THC-dimethylheptyl); SR, SR141716A.

[2] References are cited below; Methodological notes: radioligand used in study: [^{3}H]CP, [^{3}H]CP55,940; [^{3}H]SR, [^{3}H]SR141716A; [^{3}H]WIN, [^{3}H]WIN55212-2; [^{3}H]HU, [^{3}H]HU243; [^{3}H]BAY, [^{3}H]BAY38-7271; [^{3}H]THC-DMH, [^{3}H]11-OH-Δ^9-THC-dimethylheptyl; [^{3}H]AEA, [^{3}H]anandamide. Note that HU210 is not HU243 (3-dimethylheptyl-11-hydroxyhexahydrocannabinol, namely reduced HU210, carrying no double bond), and HU210 is not equivalent to 11-OH-Δ^9-THC-DMH.

Tissues or cells used in study were native or transfected. Native included: A = brain homogenates (unspecified), B = whole brain homogenates, C = cerebrum (cortical) homogenates or 'forebrain' homogenates, D = cerebellum homogenates, E = hippocampus homogenates, F = cortex and caudate-putamen slices, G = neuroblastoma (*Mm* N18TG2 or N1E-115) cells, H = *Hs* monocyte (U937) cells, J = whole spleen homogenates, K = splenocyte homogenates, L = tonsil homogenates, M = leukemia cells, N = *Rn* RBL-2H3 leukemia cells. Transfected cells included: 0 = cell type not specified, 1 = AtT-20 cells, 2 = CHO cells, 3 = COS cells, 4 = HEK-293 cells, 5 = LtK cells, 6 = *Xenopus* oocytes, 7 = Sf9 cells.

"Sect" indicates tissues were slide-mounted as sections or minced, rather than homogenized into membrane pellets.

"Centri" indicates free and bound radioligand was separated by centrifugation, rather than rapid filtration.

"ØPMSF" indicates the absence of phenylmethylsulfonyl fluoride or no statement concerning its use, whereas "+PMSF" indicates the presence of PMSF or another endocannabinoid enzyme inhibitor.

[3] ligand affinity measured in nM units, as Kd or Ki ("Kd" and "Ki" differentiated when indicated, and the rest are Ki measurements); followed by n = sample size (number of independent experiments); followed by measure of variance reported in the study: SD = standard deviation, SE = standard error (SD = SE x √n), S? = variance not specified in original publication; confidence intervals (95%) were transformed to standard errors using the formula SE = (upper limit – lower limit)/3.92.

[4] Direct comparisons: *H1:R1* indicates original study compared ligand affinity at *Hs*CB_1 versus *Rn*CB_1; *H2:R2* indicates original study compared ligand affinity at *Hs*CB_2 versus *Rn*CB_2; *Hs1:2:* indicates original study compared ligand affinity at *Hs*CB_1 versus *Hs*CB_2; *Rn1:2:* indicates original study compared ligand affinity at *Rn*CB_1 versus *Rn*CB_2. Comparisons include: T = transfected receptor, N = native receptor; comparisons are presented as ratios.

[5] Studies that used [^{3}H]Δ^8-THC or [^{3}H]TMA ([^{3}H]-5'-trimethylammonium Δ^9-THC) are presented here for historical interest and were not subjected to data synthesis. These ligands did not exhibit saturability or proved irrelevant in typical animal behavioral models of cannabinoid activity.

Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L. A., Pertwee, R. G. and Makriyannis, A. (1994). (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. *J Med Chem,* **37,** 1889-93.

Abadji, V., Lucas-Lenard, J. M., Chin, C. and Kendall, D. A. (1999). Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. *J Neurochem,* **72,** 2032-8.

Adams, I. B., Compton, D. R. and Martin, B. R. (1998). Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. *J Pharmacol Exp Ther,* **284,** 1209-17.

Adams, I. B., Ryan, W., Singer, M., Razdan, R. K., Compton, D. R. and Martin, B. R. (1995a). Pharmacological and behavioral evaluation of alkylated anandamide analogs. *Life Sci,* **56,** 2041-8.

Adams, I. B., Ryan, W., Singer, M., Thomas, B. F., Compton, D. R., Razdan, R. K. and Martin, B. R. (1995b). Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. *J Pharmacol Exp Ther,* **273,** 1172-81.

Andersson, H., D'Antona, A. M., Kendall, D. A., Von Heijne, G. and Chin, C. N. (2003). Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. *Mol Pharmacol,* **64,** 570-7.

Appendino, G., Ligresti, A., Minassi, A., Daddario, N., Bisogno, T. and Di Marzo, V. (2003). Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat cannabinoid CB(1) receptors. *Bioorg Med Chem Lett,* **13,** 43-6.

Appendino, G., Minassi, A., Berton, L., Moriello, A. S., Cascio, M. G., De Petrocellis, L. and Di Marzo, V. (2006). Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. *J Med Chem,* **49,** 2333-8.

Bari, M., Battista, N., Fezza, F., Finazzi-Agro, A. and Maccarrone, M. (2005). Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. *J Biol Chem,* **280,** 12212-20.

Bayewitch, M., Avidor-Reiss, T., Levy, R., Barg, J., Mechoulam, R. and Vogel, Z. (1995). The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. *FEBS Lett,* **375,** 143-7.

Bayewitch, M., Rhee, M. H., Avidor-Reiss, T., Breuer, A., Mechoulam, R. and Vogel, Z. (1996). (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. *J Biol Chem,* **271,** 9902-5.

Belue, R. C., Howlett, A. C., Westlake, T. M. and Hutchings, D. E. (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. *Neurotoxicol Teratol,* **17,** 25-30.

Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M. H., Vogel, Z., Bisogno, T., De Petrocellis, L., Di Marzo, V. and Mechoulam, R. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. *Eur J Pharmacol,* **353,** 23-31.

Berglund, B. A., Boring, D. L., Wilken, G. H., Makriyannis, A., Howlett, A. C. and Lin, S. (1998). Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. *Prostaglandins Leukot Essent Fatty Acids,* **59,** 111-8.

Bezuglov, V., Bobrov, M., Gretskaya, N., Gonchar, A., Zinchenko, G., Melck, D., Bisogno, T., Di Marzo, V., Kuklev, D., Rossi, J. C., Vidal, J. P. and Durand, T. (2001). Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. *Bioorg Med Chem Lett,* **11,** 447-9.

Bidaut-Russell, M., Devane, W. A. and Howlett, A. C. (1990). Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. *J Neurochem,* **55,** 21-6.

Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R. and Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol,* **134,** 845-52.

Bisogno, T., Melck, D., Bobrov, M., Gretskaya, N. M., Bezuglov, V. V., De Petrocellis, L. and Di Marzo, V. (2000). N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. *Biochem J,* **351 Pt 3,** 817-24.

Bobrov, M., Gretskaya, N., Payet, O., Bezuglov, V., Durand, T., Maurin, L., Tourrel, F., Adjali, O., Rinaldi-Carmona, M. and Muller, A. (2005). Different pharmacological profile of two closely related endocannabinoid ester analogs. *Life Sci,* **77,** 1425-40.

Bonhaus, D. W., Chang, L. K., Kwan, J. and Martin, G. R. (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. *J Pharmacol Exp Ther,* **287,** 884-8.

Boring, D. L., Berglund, B. A. and Howlett, A. C. (1996). Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors. *Prostaglandins Leukot Essent Fatty Acids,* **55,** 207-10.

Bouaboula, M., Bourrie, B., Rinaldi-Carmona, M., Shire, D., Le Fur, G. and Casellas, P. (1995a). Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. *J Biol Chem,* **270,** 13973-80.

Bouaboula, M., Poinot-Chazel, C., Bourrie, B., Canat, X., Calandra, B., Rinaldi-Carmona, M., Le Fur, G. and Casellas, P. (1995b). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. *Biochem J,* **312 (Pt 2),** 637-41.

Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bourrie, B., Rinaldi-Carmona, M., Calandra, B., Le Fur, G. and Casellas, P. (1996). Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. *Eur J Biochem,* **237,** 704-11.

Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., Le Fur, G. and Casellas, P. (1993). Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem,* **214,** 173-80.

Breivogel, C. S. and Childers, S. R. (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. *J Pharmacol Exp Ther,* **295,** 328-36.

Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., Vogt, L. J. and Sim-Selley, L. J. (1999). Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. *J Neurochem,* **73,** 2447-59.

Breivogel, C. S., Scates, S. M., Beletskaya, I. O., Lowery, O. B., Aceto, M. D. and Martin, B. R. (2003). The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. *Eur J Pharmacol,* **459,** 139-50.

Breivogel, C. S., Sim, L. J. and Childers, S. R. (1997). Regional differences in cannabinoid receptor/G-protein coupling in rat brain. *J Pharmacol Exp Ther,* **282,** 1632-42.

Bridgen, T., Fan, F., Compton, D. R. and Martin, B. R. (1990). Competitive inhibition of cannabinoid binding in a novel filtration assay. *FASEB Journal,* **4,** A996.

Brizzi, A., Brizzi, V., Cascio, M. G., Bisogno, T., Sirianni, R. and Di Marzo, V. (2005). Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. *J Med Chem,* **48,** 7343-50.

Busch, L., Sterin-Borda, L. and Borda, E. (2004). Expression and biological effects of CB1 cannabinoid receptor in rat parotid gland. *Biochem Pharmacol,* **68,** 1767-74.

Childers, S. R., Sexton, T. and Roy, M. B. (1994). Effects of anandamide on cannabinoid receptors in rat brain membranes. *Biochem Pharmacol,* **47,** 711-5.

Chin, C. N., Lucas-Lenard, J., Abadji, V. and Kendall, D. A. (1998). Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. *J Neurochem,* **70,** 366-73.

Chin, C. N., Murphy, J. W., Huffman, J. W. and Kendall, D. A. (1999). The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. *J Pharmacol Exp Ther,* **291,** 837-44.

Compton, D. R., Rice, K. C., De Costa, B. R., Razdan, R. K., Melvin, L. S., Johnson, M. R. and Martin, B. R. (1993). Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. *J Pharmacol Exp Ther,* **265,** 218-26.

D'Ambra, T. E., Estep, K. G., Bell, M. R., Eissenstat, M. A., Josef, K. A., Ward, S. J., Haycock, D. A., Baizman, E. R., Casiano, F. M., Beglin, N. C. and et al. (1992). Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. *J Med Chem,* **35,** 124-35.

D'Antona, A. M., Ahn, K. H. and Kendall, D. A. (2006). Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. *Biochemistry,* **45,** 5606-17.

De Vry, J., Denzer, D., Reissmueller, E., Eijckenboom, M., Heil, M., Meier, H. and Mauler, F. (2004). 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfo nate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. *J Pharmacol Exp Ther,* **310,** 620-32.

Deng, H., Gifford, A. N., Zvonok, A. M., Cui, G., Li, X., Fan, P., Deschamps, J. R., Flippen-Anderson, J. L., Gatley, S. J. and Makriyannis, A. (2005). Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. *J Med Chem,* **48,** 6386-92.

Deutsch, D. G., Goligorsky, M. S., Schmid, P. C., Krebsbach, R. J., Schmid, H. H., Das, S. K., Dey, S. K., Arreaza, G., Thorup, C., Stefano, G. and Moore, L. C. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. *J Clin Invest,* **100,** 1538-46.

Devane, W. A., Breuer, A., Sheskin, T., Jarbe, T. U., Eisen, M. S. and Mechoulam, R. (1992a). A novel probe for the cannabinoid receptor. *J Med Chem,* **35,** 2065-9.

Devane, W. A., Dysarz, F. A., 3rd, Johnson, M. R., Melvin, L. S. and Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol,* **34,** 605-13.

Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992b). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science,* **258,** 1946-9.

Devlin, M. G. and Christopoulos, A. (2002). Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. *J Neurochem,* **80,** 1095-102.

Di Marzo, V., Lastres-Becker, I., Bisogno, T., De Petrocellis, L., Milone, A., Davis, J. B. and Fernandez-Ruiz, J. J. (2001). Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. *Eur J Pharmacol,* **420,** 123-31.

Dutta, A. K., Ryan, W., Thomas, B. F., Singer, M., Compton, D. R., Martin, B. R. and Razdan, R. K. (1997). Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs). *Bioorg Med Chem,* **5,** 1591-600.

Dyson, A., Peacock, M., Chen, A., Courade, J. P., Yaqoob, M., Groarke, A., Brain, C., Loong, Y. and Fox, A. (2005). Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. *Pain,* **116,** 129-37.

Edgemond, W. S., Hillard, C. J., Falck, J. R., Kearn, C. S. and Campbell, W. B. (1998). Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. *Mol Pharmacol,* **54,** 180-8.

Ellis, J., Pediani, J. D., Canals, M., Milasta, S. and Milligan, G. (2006). Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. *J Biol Chem,* **281,** 38812-24.

Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D. and Leon, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. *Proc Natl Acad Sci U S A,* **92,** 3376-80.

Fay, J. F., Dunham, T. D. and Farrens, D. L. (2005). Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. *Biochemistry,* **44,** 8757-69.

Felder, C. C., Briley, E. M., Axelrod, J., Simpson, J. T., Mackie, K. and Devane, W. A. (1993). Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. *Proc Natl Acad Sci U S A,* **90,** 7656-60.

Felder, C. C., Joyce, K. E., Briley, E. M., Glass, M., Mackie, K. P., Fahey, K. J., Cullinan, G. J., Hunden, D. C., Johnson, D. W., Chaney, M. O., Koppel, G. A. and Brownstein, M. (1998). LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. *J Pharmacol Exp Ther,* **284,** 291-7.

Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L. and Mitchell, R. L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. *Mol Pharmacol,* **48,** 443-50.

Felder, C. C., Veluz, J. S., Williams, H. L., Briley, E. M. and Matsuda, L. A. (1992). Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. *Mol Pharmacol,* **42,** 838-45.

Feng, W. and Song, Z. H. (2001). Functional roles of the tyrosine within the NP(X)(n)Y motif and the cysteines in the C-terminal juxtamembrane region of the CB2 cannabinoid receptor. *FEBS Lett,* **501,** 166-70.

Feng, W. and Song, Z. H. (2003). Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor. *Biochem Pharmacol,* **65,** 1077-85.

Fowler, C. J., Nilsson, O., Andersson, M., Disney, G., Jacobsson, S. O. and Tiger, G. (2001). Pharmacological properties of cannabinoid receptors in the avian brain: similarity of rat and chicken cannabinoid1 receptor recognition sites and expression of cannabinoid2 receptor-like immunoreactivity in the embryonic chick brain. *Pharmacol Toxicol,* **88,** 213-22.

Francisco, M. E., Seltzman, H. H., Gilliam, A. F., Mitchell, R. A., Rider, S. L., Pertwee, R. G., Stevenson, L. A. and Thomas, B. F. (2002). Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxami de (SR141716). *J Med Chem,* **45,** 2708-19.

Fride, E., Ponde, D., Breuer, A. and Hanus, L. (2005). Peripheral, but not central effects of cannabidiol derivatives: Mediation by CB(1) and unidentified receptors. *Neuropharmacology,* **48,** 1117-29.

Gerard, C. M., Mollereau, C., Vassart, G. and Parmentier, M. (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. *Biochem J,* **279 (Pt 1),** 129-34.

Gifford, A. N., Tang, Y., Gatley, S. J., Volkow, N. D., Lan, R. and Makriyannis, A. (1997). Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. *Neurosci Lett,* **238,** 84-6.

Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D. and Hipkin, R. W. (2000). Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. *Mol Pharmacol,* **57,** 1045-50.

Govaerts, S. J., Hermans, E. and Lambert, D. M. (2004a). Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. *Eur J Pharm Sci,* **23,** 233-43.

Govaerts, S. J., Muccioli, G. G., Hermans, E. and Lambert, D. M. (2004b). Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors. *Eur J Pharmacol,* **495,** 43-53.

Griffin, G., Tao, Q. and Abood, M. E. (2000). Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. *J Pharmacol Exp Ther,* **292,** 886-94.

Griffin, G., Wray, E. J., Martin, B. R. and Abood, M. E. (1999a). Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. *Br J Pharmacol,* **128,** 684-8.

Griffin, G., Wray, E. J., Tao, Q., McAllister, S. D., Rorrer, W. K., Aung, M. M., Martin, B. R. and Abood, M. E. (1999b). Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. *Eur J Pharmacol,* **377,** 117-25.

Hampson, A. J., Hill, W. A., Zan-Phillips, M., Makriyannis, A., Leung, E., Eglen, R. M. and Bornheim, L. M. (1995). Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. *Biochim Biophys Acta,* **1259,** 173-9.

Harris, L. S., Carchman, R. A. and Martin, B. R. (1978). Evidence for the existence of specific cannabinoid binding sites. *Life Sci,* **22,** 1131-7.

Haycock, D. A., Kuster, J. E., Stevenson, J. I., Ward, S. J. and D'Ambra, T. (1990). Characterization of aminoalkylindole binding: selective displacement by cannabinoids. *NIDA Res Monogr,* **105,** 304-5.

Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R. and Rice, K. C. (1990). Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A,* **87,** 1932-6.

Hill, M. N., Ho, W. S., Meier, S. E., Gorzalka, B. B. and Hillard, C. J. (2005a). Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. *Eur J Pharmacol,* **528,** 99-102.

Hill, M. N., Ho, W. S., Sinopoli, K. J., Viau, V., Hillard, C. J. and Gorzalka, B. B. (2006). Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. *Neuropsychopharmacology,* **31,** 2591-9.

Hill, M. N., Patel, S., Carrier, E. J., Rademacher, D. J., Ormerod, B. K., Hillard, C. J. and Gorzalka, B. B. (2005b). Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. *Neuropsychopharmacology,* **30,** 508-15.

Hillard, C. J., Edgemond, W. S. and Campbell, W. B. (1995). Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. *J Neurochem,* **64,** 677-83.

Hillard, C. J., Manna, S., Greenberg, M. J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G. and Campbell, W. B. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). *J Pharmacol Exp Ther,* **289,** 1427-33.

Hirst, R. A., Almond, S. L. and Lambert, D. G. (1996). Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. *Neurosci Lett,* **220,** 101-4.

Ho, B. Y., Current, L. and Drewett, J. G. (2002). Role of intracellular loops of cannabinoid CB(1) receptor in functional interaction with G(alpha16). *FEBS Lett,* **522,** 130-4.

Houston, D. B., Evans, D. M., Howlett, A. C. and Melvin, L. S. (1991). 3H]CP55940 binding to the cannabinoid receptor. *Dupont Biotech Update,* **6,** 21-27.

Houston, D. B. and Howlett, A. C. (1992). Solubilization of the cannabinoid receptor from rat brain membranes. *Ann N Y Acad Sci,* **654,** 448-50.

Houston, D. B. and Howlett, A. C. (1993). Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. *Mol Pharmacol,* **43,** 17-22.

Houston, D. B. and Howlett, A. C. (1998). Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. *Cell Signal,* **10,** 667-74.

Hungund, B. L., Vinod, K. Y., Kassir, S. A., Basavarajappa, B. S., Yalamanchili, R., Cooper, T. B., Mann, J. J. and Arango, V. (2004). Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. *Mol Psychiatry,* **9,** 184-90.

Hurst, D., Umejiego, U., Lynch, D., Seltzman, H., Hyatt, S., Roche, M., McAllister, S., Fleischer, D., Kapur, A., Abood, M., Shi, S., Jones, J., Lewis, D. and Reggio, P. (2006). Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. *J Med Chem,* **49,** 5969-87.

Hurst, D. P., Lynch, D. L., Barnett-Norris, J., Hyatt, S. M., Seltzman, H. H., Zhong, M., Song, Z. H., Nie, J., Lewis, D. and Reggio, P. H. (2002). N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. *Mol Pharmacol,* **62,** 1274-87.

Iwamura, H., Suzuki, H., Ueda, Y., Kaya, T. and Inaba, T. (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. *J Pharmacol Exp Ther,* **296,** 420-5.

Jansen, E. M., Haycock, D. A., Ward, S. J. and Seybold, V. S. (1992). Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. *Brain Res,* **575,** 93-102.

Jung, M., Calassi, R., Rinaldi-Carmona, M., Chardenot, P., Le Fur, G., Soubrie, P. and Oury-Donat, F. (1997). Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A. *J Neurochem,* **68,** 402-9.

Kanyonyo, M., Govaerts, S. J., Hermans, E., Poupaert, J. H. and Lambert, D. M. (1999). 3-Alkyl-(5,5'-diphenyl)imidazolidineiones as new cannabinoid receptor ligands. *Bioorg Med Chem Lett,* **9,** 2233-6.

Kathmann, M., Bauer, U. and Schlicker, E. (1999a). CB1 receptor density and CB1 receptor-mediated functional effects in rat hippocampus are decreased by an intracerebroventricularly administered antisense oligodeoxynucleotide. *Naunyn Schmiedebergs Arch Pharmacol,* **360,** 421-7.

Kathmann, M., Bauer, U., Schlicker, E. and Gothert, M. (1999b). Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. *Naunyn Schmiedebergs Arch Pharmacol,* **359,** 466-70.

Kearn, C. S., Greenberg, M. J., DiCamelli, R., Kurzawa, K. and Hillard, C. J. (1999). Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. *J Neurochem,* **72,** 2379-87.

Khanolkar, A. D., Abadji, V., Lin, S., Hill, W. A., Taha, G., Abouzid, K., Meng, Z., Fan, P. and Makriyannis, A. (1996). Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. *J Med Chem,* **39,** 4515-9.

Koutek, B., Prestwich, G. D., Howlett, A. C., Chin, S. A., Salehani, D., Akhavan, N. and Deutsch, D. G. (1994). Inhibitors of arachidonoyl ethanolamide hydrolysis. *J Biol Chem,* **269,** 22937-40.

Kuster, J. E., Stevenson, J. I., Ward, S. J., D'Ambra, T. E. and Haycock, D. A. (1993). Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. *J Pharmacol Exp Ther,* **264,** 1352-63.

Lambert, D. M. and Di Marzo, V. (1999). The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? *Curr Med Chem,* **6,** 757-73.

Lambert, D. M., DiPaolo, F. G., Sonveaux, P., Kanyonyo, M., Govaerts, S. J., Hermans, E., Bueb, J., Delzenne, N. M. and Tschirhart, E. J. (1999). Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. *Biochim Biophys Acta,* **1440,** 266-74.

Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S. R., McCallion, D., Pertwee, R. and Makriyannis, A. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. *J Med Chem,* **42,** 769-76.

Lange, J. H., van Stuivenberg, H. H., Coolen, H. K., Adolfs, T. J., McCreary, A. C., Keizer, H. G., Wals, H. C., Veerman, W., Borst, A. J., de Looff, W., Verveer, P. C. and Kruse, C. G. (2005). Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. *J Med Chem,* **48,** 1823-38.

Leggett, J. D., Aspley, S., Beckett, S. R., D'Antona, A. M. and Kendall, D. A. (2004). Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. *Br J Pharmacol,* **141,** 253-62.

Lin, S., Khanolkar, A. D., Fan, P., Goutopoulos, A., Qin, C., Papahadjis, D. and Makriyannis, A. (1998). Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. *J Med Chem,* **41,** 5353-61.

Lu, R., Hubbard, J. R., Martin, B. R. and Kalimi, M. Y. (1993). Roles of sulfhydryl and disulfide groups in the binding of CP-55,940 to rat brain cannabinoid receptor. *Mol Cell Biochem,* **121,** 119-26.

Lunn, C. A., Fine, J. S., Rojas-Triana, A., Jackson, J. V., Fan, X., Kung, T. T., Gonsiorek, W., Schwarz, M. A., Lavey, B., Kozlowski, J. A., Narula, S. K., Lundell, D. J., Hipkin, R. W. and Bober, L. A. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. *J Pharmacol Exp Ther,* **316,** 780-8.

Lynn, A. B. and Herkenham, M. (1994). Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. *J Pharmacol Exp Ther,* **268,** 1612-23.

MacLennan, S. J., Reynen, P. H., Kwan, J. and Bonhaus, D. W. (1998). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. *Br J Pharmacol,* **124,** 619-22.

Marchese, G., Casti, P., Ruiu, S., Saba, P., Sanna, A., Casu, G. and Pani, L. (2003). Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. *Br J Pharmacol,* **140,** 520-6.

Martin, B. R., Compton, D. R., Thomas, B. F., Prescott, W. R., Little, P. J., Razdan, R. K., Johnson, M. R., Melvin, L. S., Mechoulam, R. and Ward, S. J. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. *Pharmacol Biochem Behav,* **40,** 471-8.

Martin, B. R., Wiley, J. L., Beletskaya, I., Sim-Selley, L. J., Smith, F. L., Dewey, W. L., Cottney, J., Adams, J., Baker, J., Hill, D., Saha, B., Zerkowski, J., Mahadevan, A. and Razdan, R. K. (2006). Pharmacological characterization of novel water-soluble cannabinoids. *J Pharmacol Exp Ther,* **318,** 1230-9.

Mauler, F., Mittendorf, J., Horvath, E. and De Vry, J. (2002). Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. *J Pharmacol Exp Ther,* **302,** 359-68.

McAllister, S. D., Tao, Q., Barnett-Norris, J., Buehner, K., Hurst, D. P., Guarnieri, F., Reggio, P. H., Nowell Harmon, K. W., Cabral, G. A. and Abood, M. E. (2002). A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. *Biochem Pharmacol,* **63,** 2121-36.

McLaughlin, C. R., Martin, B. R., Compton, D. R. and Abood, M. E. (1994). Cannabinoid receptors in developing rats: detection of mRNA and receptor binding. *Drug Alcohol Depend,* **36,** 27-31.

Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R. and et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol,* **50,** 83-90.

Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M. and Di Marzo, V. (2000). Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. *Endocrinology,* **141,** 118-26.

Melvin, L. S., Milne, G. M., Johnson, M. R., Subramaniam, B., Wilken, G. H. and Howlett, A. C. (1993). Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. *Mol Pharmacol,* **44,** 1008-15.

Meschler, J. P., Kraichely, D. M., Wilken, G. H. and Howlett, A. C. (2000). Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. *Biochem Pharmacol,* **60,** 1315-23.

Muccioli, G. G., Martin, D., Scriba, G. K., Poppitz, W., Poupaert, J. H., Wouters, J. and Lambert, D. M. (2005). Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation. *J Med Chem,* **48,** 2509-17.

Muhammad, I., Li, X. C., Dunbar, D. C., ElSohly, M. A. and Khan, I. A. (2001). Antimalarial (+)-trans-hexahydrodibenzopyran derivatives from Machaerium multiflorum. *J Nat Prod,* **64,** 1322-5.

Mukherjee, S., Adams, M., Whiteaker, K., Daza, A., Kage, K., Cassar, S., Meyer, M. and Yao, B. B. (2004). Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. *Eur J Pharmacol,* **505,** 1-9.

Munro, S., Thomas, K. L. and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. *Nature,* **365,** 61-5.

Murphy, J. W. and Kendall, D. A. (2003). Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A. *Biochem Pharmacol,* **65,** 1623-31.

Nebane, N. M., Kellie, B. and Song, Z. H. (2006). The effects of charge-neutralizing mutation D6.30N on the functions of CB1 and CB2 cannabinoid receptors. *FEBS Lett,* **580,** 5392-8.

Nowell, K. W., Pettit, D. A., Cabral, W. A., Zimmerman, H. W., Jr., Abood, M. E. and Cabral, G. A. (1998). High-level expression of the human CB2 cannabinoid receptor using a baculovirus system. *Biochem Pharmacol,* **55,** 1893-905.

Nye, J. S., Seltzman, H. H., Pitt, C. G. and Snyder, S. H. (1985). High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5'-trimethylammonium delta 8-tetrahydrocannabinol. *J Pharmacol Exp Ther,* **234,** 784-91.

Ooms, F., Wouters, J., Oscari, O., Happaerts, T., Bouchard, G., Carrupt, P. A., Testa, B. and Lambert, D. M. (2002). Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling. *J Med Chem,* **45,** 1748-56.

Oviedo, A., Glowa, J. and Herkenham, M. (1993). Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. *Brain Res,* **616,** 293-302.

Paugh, S. W., Cassidy, M. P., He, H., Milstien, S., Sim-Selley, L. J., Spiegel, S. and Selley, D. E. (2006). Sphingosine and Its Analog, the Immunosuppressant 2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, Interact with the CB1 Cannabinoid Receptor. *Mol Pharmacol,* **70,** 41-50.

Petitet, F., Marin, L. and Doble, A. (1996). Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A. *Neuroreport,* **7,** 789-92.

Pettit, D. A., Showalter, V. M., Abood, M. E. and Cabral, G. A. (1994). Expression of a cannabinoid receptor in baculovirus-infected insect cells. *Biochem Pharmacol,* **48,** 1231-43.

Picone, R. P., Khanolkar, A. D., Xu, W., Ayotte, L. A., Thakur, G. A., Hurst, D. P., Abood, M. E., Reggio, P. H., Fournier, D. J. and Makriyannis, A. (2005). (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. *Mol Pharmacol,* **68,** 1623-35.

Priller, J., Briley, E. M., Mansouri, J., Devane, W. A., Mackie, K. and Felder, C. C. (1995). Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors. *Mol Pharmacol,* **48,** 288-92.

Raduner, S., Majewska, A., Chen, J. Z., Xie, X. Q., Hamon, J., Faller, B., Altmann, K. H. and Gertsch, J. (2006). Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. *J Biol Chem,* **281,** 14192-206.

Reggio, P. H., Basu-Dutt, S., Barnett-Norris, J., Castro, M. T., Hurst, D. P., Seltzman, H. H., Roche, M. J., Gilliam, A. F., Thomas, B. F., Stevenson, L. A., Pertwee, R. G. and Abood, M. E. (1998). The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. *J Med Chem,* **41,** 5177-87.

Rhee, M. H., Nevo, I., Bayewitch, M. L., Zagoory, O. and Vogel, Z. (2000a). Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor. *J Neurochem,* **75,** 2485-91.

Rhee, M. H., Nevo, I., Levy, R. and Vogel, Z. (2000b). Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of the CB2 cannabinoid receptor. *FEBS Lett,* **466,** 300-4.

Rhee, M. H., Vogel, Z., Barg, J., Bayewitch, M., Levy, R., Hanus, L., Breuer, A. and Mechoulam, R. (1997). Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. *J Med Chem,* **40,** 3228-33.

Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D. and et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. *FEBS Lett,* **350,** 240-4.

Rinaldi-Carmona, M., Calandra, B., Shire, D., Bouaboula, M., Oustric, D., Barth, F., Casellas, P., Ferrara, P. and Le Fur, G. (1996a). Characterization of two cloned human CB1 cannabinoid receptor isoforms. *J Pharmacol Exp Ther,* **278,** 871-8.

Rinaldi-Carmona, M., Le Duigou, A., Oustric, D., Barth, F., Bouaboula, M., Carayon, P., Casellas, P. and Le Fur, G. (1998). Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. *J Pharmacol Exp Ther,* **287,** 1038-47.

Rinaldi-Carmona, M., Pialot, F., Congy, C., Redon, E., Barth, F., Bachy, A., Breliere, J. C., Soubrie, P. and Le Fur, G. (1996b). Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. *Life Sci,* **58,** 1239-47.

Roche, J. P., Bounds, S., Brown, S. and Mackie, K. (1999). A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. *Mol Pharmacol,* **56,** 611-8.

Rodriguez de Fonseca, F., Cebeira, M., Ramos, J. A., Martin, M. and Fernandez-Ruiz, J. J. (1994a). Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. *Life Sci,* **54,** 159-70.

Rodriguez de Fonseca, F., Gorriti, M. A., Fernandez-Ruiz, J. J., Palomo, T. and Ramos, J. A. (1994b). Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. *Pharmacol Biochem Behav,* **47,** 33-40.

Rodriguez de Fonseca, F., Ramos, J. A., Bonnin, A. and Fernandez-Ruiz, J. J. (1993). Presence of cannabinoid binding sites in the brain from early postnatal ages. *Neuroreport,* **4,** 135-8.

Romero, J., Garcia, L., Fernandez-Ruiz, J. J., Cebeira, M. and Ramos, J. A. (1995). Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol. *Pharmacol Biochem Behav,* **51,** 731-7.

Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, F., Makriyannis, A. and Pertwee, R. G. (1999a). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. *Br J Pharmacol,* **126,** 665-72.

Ross, R. A., Gibson, T. M., Stevenson, L. A., Saha, B., Crocker, P., Razdan, R. K. and Pertwee, R. G. (1999b). Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. *Br J Pharmacol,* **128,** 735-43.

Ryberg, E., Vu, H. K., Larsson, N., Groblewski, T., Hjorth, S., Elebring, T., Sjogren, S. and Greasley, P. J. (2005). Identification and characterisation of a novel splice variant of the human CB1 receptor. *FEBS Lett,* **579,** 259-64.

Savinainen, J. R., Kokkola, T., Salo, O. M., Poso, A., Jarvinen, T. and Laitinen, J. T. (2005). Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. *Br J Pharmacol,* **145,** 636-45.

Seltzman, H. H., Fleming, D. N., Thomas, B. F., Gilliam, A. F., McCallion, D. S., Pertwee, R. G., Compton, D. R. and Martin, B. R. (1997). Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. *J Med Chem,* **40,** 3626-34.

Shen, C. P., Xiao, J. C., Armstrong, H., Hagmann, W. and Fong, T. M. (2006). F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist. *Eur J Pharmacol,* **531,** 41-6.

Sheskin, T., Hanus, L., Slager, J., Vogel, Z. and Mechoulam, R. (1997). Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. *J Med Chem,* **40,** 659-67.

Shim, J. Y., Collantes, E. R., Welsh, W. J., Subramaniam, B., Howlett, A. C., Eissenstat, M. A. and Ward, S. J. (1998). Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis. *J Med Chem,* **41,** 4521-32.

Shim, J. Y., Welsh, W. J., Cartier, E., Edwards, J. L. and Howlett, A. C. (2002). Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. *J Med Chem,* **45,** 1447-59.

Shire, D., Calandra, B., Delpech, M., Dumont, X., Kaghad, M., Le Fur, G., Caput, D. and Ferrara, P. (1996a). Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. *J Biol Chem,* **271,** 6941-6.

Shire, D., Calandra, B., Rinaldi-Carmona, M., Oustric, D., Pessegue, B., Bonnin-Cabanne, O., Le Fur, G., Caput, D. and Ferrara, P. (1996b). Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. *Biochim Biophys Acta,* **1307,** 132-6.

Shoemaker, J. L., Joseph, B. K., Ruckle, M. B., Mayeux, P. R. and Prather, P. L. (2005). The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. *J Pharmacol Exp Ther,* **314,** 868-75.

Showalter, V. M., Compton, D. R., Martin, B. R. and Abood, M. E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. *J Pharmacol Exp Ther,* **278,** 989-99.

Slipetz, D. M., O'Neill, G. P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay, D., Labelle, M. and Metters, K. M. (1995). Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. *Mol Pharmacol,* **48,** 352-61.

Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulam, R. and Martin, B. R. (1994). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. *J Pharmacol Exp Ther,* **270,** 219-27.

Song, Z. H. and Bonner, T. I. (1996). A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. *Mol Pharmacol,* **49,** 891-6.

Song, Z. H. and Feng, W. (2002). Absence of a conserved proline and presence of a conserved tyrosine in the CB2 cannabinoid receptor are crucial for its function. *FEBS Lett,* **531,** 290-4.

Song, Z. H., Slowey, C. A., Hurst, D. P. and Reggio, P. H. (1999). The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). *Mol Pharmacol,* **56,** 834-40.

Steffens, M., Engler, C., Zentner, J. and Feuerstein, T. J. (2004). Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. *Br J Pharmacol,* **141,** 1193-203.

Steffens, M., Zentner, J., Honegger, J. and Feuerstein, T. J. (2005). Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor. *Biochem Pharmacol,* **69,** 169-78.

Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. and Waku, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun,* **215,** 89-97.

Tao, Q. and Abood, M. E. (1998). Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. *J Pharmacol Exp Ther,* **285,** 651-8.

Tao, Q., McAllister, S. D., Andreassi, J., Nowell, K. W., Cabral, G. A., Hurst, D. P., Bachtel, K., Ekman, M. C., Reggio, P. H. and Abood, M. E. (1999). Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. *Mol Pharmacol,* **55,** 605-13.

Thomas, B. F., Francisco, M. E., Seltzman, H. H., Thomas, J. B., Fix, S. E., Schulz, A. K., Gilliam, A. F., Pertwee, R. G. and Stevenson, L. A. (2005). Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyra zole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. *Bioorg Med Chem,* **13,** 5463-74.

Thomas, B. F., Gilliam, A. F., Burch, D. F., Roche, M. J. and Seltzman, H. H. (1998). Comparative receptor binding analyses of cannabinoid agonists and antagonists. *J Pharmacol Exp Ther,* **285,** 285-92.

Thomas, B. F., Wei, X. and Martin, B. R. (1992). Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [3H]11-OH-delta 9-THC-DMH. *J Pharmacol Exp Ther,* **263,** 1383-90.

Valenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., Rabadi, L., Rotshteyn, Y., Chaffer, S. M., Turchin, P. I., Elsemore, D. A., Toth, M., Koetzner, L. and Whiteside, G. T. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. *Neuropharmacology,* **48,** 658-72.

van der Stelt, M., van Kuik, J. A., Bari, M., van Zadelhoff, G., Leeflang, B. R., Veldink, G. A., Finazzi-Agro, A., Vliegenthart, J. F. and Maccarrone, M. (2002). Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. *J Med Chem,* **45,** 3709-20.

Vinod, K. Y., Arango, V., Xie, S., Kassir, S. A., Mann, J. J., Cooper, T. B. and Hungund, B. L. (2005). Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. *Biol Psychiatry,* **57,** 480-6.

Vogel, Z., Barg, J., Levy, R., Saya, D., Heldman, E. and Mechoulam, R. (1993). Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. *J Neurochem,* **61,** 352-5.

Vogel, Z., Bayewitch, M., Levy, R., Matusleibovitch, N., Hanus, L., Ben-Shabat, S., Mechoulam, R., Avidor-Reiss, T. and Barg, J. (1994). Binding and functional studies with peripheral and neuronal cannabinoid receptors. *Regul Pept,* **54,** 313-314.

Welch, S. P., Dunlow, L. D., Patrick, G. S. and Razdan, R. K. (1995). Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. *J Pharmacol Exp Ther,* **273,** 1235-44.

Wise, M. L., Soderstrom, K., Murray, T. F. and Gerwick, W. H. (1996). Synthesis and cannabinoid receptor binding activity of conjugated triene anandamide, a novel eicosanoid. *Experientia,* **52,** 88-92.